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Abstract 
Oxaliplatin is routinely prescribed for the treatment and management of metastatic 
colorectal cancers; however, long-term clinical use is impeded by the development of 
acute and chronic peripheral neuropathies. Although the mechanisms responsible for 
symptom development are unclear, platinum accumulation in nervous tissues is a 
potential pain-state contributor. It is not known where in the dorsal root ganglion (DRG) 
platinum from oxaliplatin accumulates, nor is it well understood what role Pt(dach)Cl2, as a 
metabolite of oxaliplatin, has in the development of oxaliplatin-induced neuropathic pain. 
This limits our understanding of the mechanisms responsible for chemotherapy-induced 
peripheral neuropathy which impinge on the development of long-lasting therapeutic 
options for patients. This study sought to develop a novel methodology for detecting 
platinum accumulation sites within rodent DRGs in an effort to refine our understanding of 
platinum/neuropathy interactions. Methods: behavioural observations were made in 21 
Long-Evans rats separated into three clusters consisting of a control and two drug-
treatments groups given either oxaliplatin (2.5mg/kg) or Pt(dach)Cl2 (2.39 mg/kg) 
intraperitoneally every three days for four injections. Immunohistochemistry was 
performed on harvested spinal cord sections for glia activation assessment while 
scanning electron microscopy, secondary ion mass spectrometry (SIMS) and mass 
spectrometry were utilised in a new methodology for identifying platinum accumulation in 
dorsal root ganglia (DRG). The former technique utilised full spectrum X-ray mapping 
coupled with energy dispersive spectroscopy to discern sites of platinum accumulation 
within DRG tissue sections. Morphometric studies of harvested DRG were also performed 
looking at eccentric nuclei and axonal G-ratios to assess the contributions of structural 
changes to neuropathy development. Results: platinum was discovered in the periphery 
of DRG cell bodies through full-spectrum X-ray analysis; however, this was at the 
detection limit of the SEM. Conversely, a larger aggregate of platinum was observed 
within the resin surrounding the DRG. Neither mass spectrometry, nor SIMS analysis 
detected platinum within DRG tissue. Astrocytitic, but not microglial, activity was 
significantly increased in the spinal cord dorsal horn following oxaliplatin-, but not 
Pt(dach)Cl2-treatments. Morphometry assessment of dorsal root ganglia tissue revealed 
slight atrophy of oxaliplatin-treated DRG cell bodies with a larger proportion of damaged 
axon fibres. However, there was no change in G-ratio between the treatment groups and 
controls, nor was any difference in C-fibre axonal area observed. Conclusions: The 
development of oxaliplatin-induced peripheral neuropathies is likely multifactorial. In the 
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current investigation four intraperitoneal injections of oxaliplatin and Pt(dach)Cl2 did not 
produce significant changes in behaviour or dorsal root ganglia cell morphology. 
However, astrocyte activation following oxaliplatin administrations were observed which 
may contribute to the development of pain states reported by other researchers. The 
development of novel techniques for the identification of platinum within DRG tissue and 
resin was successful using full spectrum X-ray mapping, which can be further refined and 
improved for future studies.     
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CHAPTER 1 
INTRODUCTION
Project aims 
This project is based on detailed experimental observations of harvested rodent spinal 
cord and dorsal root ganglia (DRG) to determine the structural and functional changes to 
nervous tissues following oxaliplatin- and Pt(dach)Cl2-treatments which may contribute to 
peripheral neuropathy development. Furthermore, this project aims to identify locations 
within rat dorsal root ganglia that preferentially accumulate platinum from oxaliplatin and 
Pt(dach)Cl2-treatments to further reveal the mechanisms behind the development of 
oxaliplatin-induced peripheral neuropathy. This later endeavour was coupled with the aim 
of developing and refining novel methodologies to investigate platinum accumulation in 
rodent dorsal root ganglia.

1.1 Anatomy of the Dorsal Root Ganglion and Spinal Cord  
Primary afferent axons can be categorised depending of their diameter, degree of 
myelination and the stimulus to which they respond (Todd 2006). Large diameter 
myelinated Aβ fibres respond preferentially to innocuous mechanical stimuli and convey 
information regarding touch, vibration and proprioception to the brain (Hoitsma et al. 
2004). Similarly, a subset of thinly myelinated Aẟ fibres respond to non-nociceptive low 
threshold stimuli such as light touch and the majority of small diameter unmyelinated C-
fibres are thermoreceptors which respond to warm and cold temperatures for 
homeostatic feedback (Michael-Titus et al. 2010). The primary role of most Aẟ and C-
fibres, however, relates to pain; Aẟ and C-fibre are activated by noxious mechanical, 
thermal and chemical stimuli (Kostyuk et al. 2001). The perception of pain is a learned 
experience and refers to actual or potential tissue damage. Aẟ fibres respond to acute 
painful stimuli (fast pain) and are active for relatively short periods of time and function in 
preventative adaptations towards pain (Michael-Titus et al. 2010; Vanderah & Gould 
2016). C-nociceptors are unmyelinated and therefore have slow conduction velocities (<2 
m/sec) (Vanderah & Gould 2016). They are partially responsible for protective adaptations 
towards painful stimuli as well as the dull ache that typically follows an acute painful 
stimulus (slow pain) (Mackenzie et al. 1975). Primary afferent axons belonging to Aβ, Aδ 
and C-fibres have cell bodies located in peripheral dorsal root ganglia (spinal ganglia) 
which give rise to a single axon that branches into peripheral and central processes 
(pseudo-unipolar sensory nerve) (Cesmebasi 2015). Central projections of primary 
afferents extend into the central nervous system (CNS) by entering into the posterior 
aspect of the spinal cord and establishing synaptic connections with interneurons within 
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the dorsal horn grey matter (Kostyuk et al. 2001). Peripheral processes extending into the 
periphery are joined by motor efferent fibres from the ventral root to form a spinal nerve.

Dorsal root ganglia contain the largest proportion of sensory neurons and respond to PNS 
signals by detecting/transducing peripheral stimuli and releasing molecules that modulate 
signal transduction (Devor 1999). However, unlike the CNS with which it interacts, the 
dorsal root ganglion is not protected by the blood-brain barrier and is therefore vulnerable 
to infiltration by large and small molecules which may promote pain (Krames 2014). For 
instance, accumulation of platinum in the DRG as a result of this barrier absence may 
contribute to platinum-based chemotherapy-induced peripheral neuropathies (Holmes et 
al. 1998; Kono et al. 2015). This is supported by work carried out by Wall and Devor 
(1983) who determined that electrical impulses could originate from within the dorsal root 
ganglion, and that these were a source of pain producing impulses following peripheral 
nerve damage.  

The spinal cord is a uniformly organised part of the central nervous system containing all 
motor neurons supplying muscles as well as receiving all sensory input from the body 
(Vanderah & Gould 2016). In 1952, Rexed presented a cytoarchitectonic scheme of the 
cat spinal cord where the grey matter was divided based on the arrangement of Nissl-
stained cell bodies in into ten regions; lamina I-X. Following some adaptation, this 
scheme of the spinal cord has been shown to be applicable to the rat spinal cord 
(Molander & Grant 1986; Grant & Koerber 2004) and also to humans. Differences and 
similarities exist between all three animals, for example, the marginal cells of lamina I in 
cats and primate species form part of the spinocerebellar tract, which is not apparent in 
rats (Brown 1982). Laminas I-III are the most densely packed spinal cord regions, with an 
estimated 57,000 neurons (Todd 2006). lamina I and II contain neurons that interact with 
primary afferent Aẟ and C-fibre axons through axodendritic and axosomatic synapses 
(Todd 2006). In detail, peptidergic C-fibres terminate in laminae I, V and the outer region 
of lamina II (IIo) while non-peptidergic C-fibres synapse with spinal cord neurons in the 
inner region of lamina II (IIi) (Latrémolière 2016). The termination of Aẟ nociceptors follows 
a similar pattern as nociceptive peptidergic C-fibres, concluding in lamina I, IIi and V 
(Todd 2006). Projection neurons have long axons that connect different areas, such as the 
spinal cord with supraspinal sites including the cortex (Vanderah & Gould 2016). Studies 
investigating the arrangement of these cells within the spinal cord have reported a 
heterogenous arrangement throughout the grey matter, with a dense population of 
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projection neurons in lamina I, almost none in lamina II and interspersed throughout the 
remaining lamina. The main ascending tracts that are concerned with transmitting 
information about painful stimuli are the spinothalamic, spinoreticular, and 
spinoparabrachial tracts (Michael-Titus et al. 2010). Lamina II spinothalamic tract neurons 
make connections with second-order projection neurons in laminae IV-VI which send 
axons across the midline through the anterior white commissure to ascend to the 
brainstem and thalamus in the anterolateral quadrant of the spinal cord (Purves et al. 
2001). All of this is summarised in fig. 1.1.1. The spinal cord, however, is not merely a wire 
on which signals are sent, instead the spinal cord has the ability to modify afferent and 
efferent signals for controlling CNS function (Nógrádi & Vrbová  2000). Additionally, the 
spinal cord may influence the perception and maintenance of pain through the activation 
of spinal glial cells following peripheral nerve injury (Bradesi 2010). 
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Figure 1.1.1. The spinal cord accompanied by ventral (red) and dorsal (blue) roots. Posterior, anterior and lateral 
funiculi constitute the spinal cord white matter, while the ventral and dorsal horns belong to spinal cord grey 
matter. Yellow line represents a primary nociceptive afferent axon with its cell body in the DRG projecting to the 
spinal cord through the dorsal root. Nociceptive afferent axons synapse with projection neurons that ascend to 
the contralateral cerebral cortex (anterior cingulate gyrus, primary somatosensory cortex, etc.) as the stimulus 
by crossing the midline of the spinal cord at the anterior white commissure and projecting to the anterolateral 
system (spinothalamic tract). I - X represent the approximate locations of Rexed laminae within the human 
spinal cord (Vanderah & Gould 2016) with lamina I-V enlarged to display the termination sites of different primary 
afferent axons (Aβ, Aẟ and C-fibres) within the dorsal horn. Lamina II is further divided into outer (IIo) and inner 
(IIi) segments.  

1.2 Oxaliplatin  
Oxaliplatin ((1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O’)platinum(II)), 
trademarked as Eloxatin, is a third-generation platinum-based chemotherapeutic used 
largely in the treatment of advanced metastatic colorectal cancers (Kawashiri et al. 2011; 
Tsubaki et al. 2015; Chen et al. 2015) and as a growing treatment option for prostatic and 
ovarian cancers (Lorusso 2000). Oxaliplatin has exhibited tumour management 
capabilities as a mono-therapy (Misset 1998) and is often paired with other compounds in 
adjuvant therapy, such as FOLFOX treatments, which consist of an intravenous injection 
of combined oxaliplaitn, folinic acid and 5-fluorouracil (Tsai et al. 2016; Starobova & Vetter 
2017). Oxaliplatin, in both treatment regimes, is cytotoxic to tumour cells by suspending 
DNA transcription through the establishment of DNA adducts within the nucleus of the 
cell (Woynarowski et al. 2000; Alcindor & Beauger 2011). Oxaliplatin induces fewer lesions 
in cellular DNA than cisplatin; however, it is also able to produce comparable cancer cell 
cytotoxicity (Woynarowski et al. 2000). Oxaliplatin was developed as an alternative to 
cisplatin and other platinum-based treatments which produce severe renal 
nephrotoxicities and gastrointestinal side-effects (Mehmood et al. 2014). Oxaliplatin does 
not exhibit similar nephrotoxicity and produces limited ototoxicity (< 3%). However, an 
acute sensory neuropathy can develop following oxaliplatin administration that typically 
regresses between cycles (Di Cesare Mannelli et al. 2013; Pachman et al. 2016). 
Continued use of the third-generation organoplatinum, however, produces  chronic motor 
and sensory neuropathies which persist between treatment cycles and often results in 
treatment discontinuation (Boyette-Davis & Dougherty 2011; Mehmood et al. 2014; 
Pachman et al. 2016).

1.3 Chemotherapy-Induced Peripheral Neuropathy 
Advancements in chemotherapy synthesis and manufacture have resulted in greater 
patient survival outcomes. However, the quality of life can be affected by the greater 
potential of developing treatment-related size-effects (Comella et al. 2009; Addington & 
Freimer 2016). Cisplatin, a widely used treatment for carcinomas, lymphomas and 
sarcomas (Dasari & Tchounwou 2014), produces a range of side-effects including 
ototoxicity, myelotoxicity, nephrotoxicity and neuropathy (Strarobova & Vetter 2017). The 
onset of these symptoms is varied, with some patients reporting drug-related 
complications after the initial dose and others after almost a full complement of 
administration cycles (Strarobova & Vetters 2017). Generally, most patients experience 
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cisplatin-related adverse symptoms following cumulative doses (350 mg/m2) (Strarobova 
& Vetters 2017). Similarly, Di Cesare Mannelli and colleagues (2013) reported chronic 
neuropathic symptoms affecting 50% of individuals when treated with cumulative doses 
of oxaliplatin greater than 1000 mg/m2. The mechanisms responsible for chemotherapy-
induced neuropathic symptoms are not well defined nor fully understood (Carozzi et al. 
2015). Oxaliplatin does not produce ototoxicity or nephrotoxicity seen in its counterpart 
cisplatin, instead oxaliplatin produces acute and chronic sensory and motor neuropathies 
(Joseph et al. 2009). Various studies have sought to identify the mechanisms responsible 
for symptom development. It is currently accepted that chemotherapy-induced peripheral 
neuropathies result from variations in neurotransmission, changes in ion channel activity 
and expression, and alterations in normal cell cytoarchitecture (Boyette-Davis et al. 2015). 
For platinum-based chemotherapeutics, nervous tissue alterations are in-part dependent 
on platinum (Kanat et al. 2017). Dorsal root ganglia are considered primary targets of 
platinum-based drugs (Carozzi et al. 2015), where platinum is believed to accumulate 
leading to sensory neuron apoptosis and nucleus and nucleolus morphometric alterations 
(Carozzi et al. 2015). Additionally, changes in DRG physiology as a result of platinum 
accumulation have been proposed as a mechanism leading to aberrant nervous tissue 
behaviour and later neuropathy development, particularly mechanical allodynia (Sakurai et 
al. 2009; Mihara et al. 2011; Carozzi et al. 2015). However, non-platinum-based 
chemotherapeutics such as the vinca alkaloids and paclitaxel also produce peripheral 
neuropathic symptoms (Scripture et al. 2006; Park et al. 2013; Rivera & Cianfrocca 2015), 
largely from the result of microtubule disruptions (Polomano & Bennett 2001; Moudi et al. 
2013). Therefore, chemotherapy-induced side effects cannot be solely explained by the 
presence of neurotoxic platinum in tissues, although for oxaliplatin, platinum is believed to 
influence the development of certain neuropathic symptoms.  

1.4 Chemistry of Oxaliplatin and Cellular interactions 
Oxaliplatin and other platinum-based chemotherapeutics, such as cisplatin, share similar 
cytotoxic capabilities and neuropathic symptom development because of their common 
structural backbone (Yonezawa & Inui 2011). Oxaliplatin consists of platinum, a 1,2 
diaminocyclohexane carrier group and a leaving group, oxalate (Kiyonari et al. 2015). 
Studies regarding oxaliplatin in both humans and rats have identified several 
biotransformation products that appear early after the administration of the drug. Two 
hours post-injection, oxaliplatin was undetectable in human plasma ultra-filtrate, although 
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its degradation products such as Pt(dach)Cl2 were found (Allen et al. 1999). Similarly, Luo 
et al. (1999a) identified Pt(dach)Cl2 and oxaliplatin in rat blood plasma shortly after 
administration; with oxaliplatin retention time reported at 18 minutes. Oxaliplatin can form 
a variety of biotransformation products known as Pt-dach complexes following the 
removal of the leaving group and additional binding of the carrier ligand to nucleophiles, 
fig. 1.4.1. It is believed that the majority of oxaliplatin is irreversibly bound to blood 
plasma and erythrocytes upon introduction to blood (Allain et al. 2000; Graham et al. 
2000).

Oxaliplatin is rapidly metabolised to oxalate and Pt(dach)Cl2 following non-enzymatic 
conversion in biological fluids (Mihara et al. 2011; Eto et al. 2014). Oxalate has been 
implicated in the development of oxaliplatin-induced cold sensitivities by disrupting nodal 
voltage-gated Na+ ion channels by rapidly chelating Ca2+ ions within cells (Argyriou et al. 
2015; Carozzi et al. 2015). Additionally, both cold and mechanical-associated pain 
developed in animal models administered with oxaliplatin but only cold hypersensitivity 
symptoms developed in rodents that received oxalate alone (Sakuari et al. 2009). The 
development of oxaliplatin-induced mechanical allodynia is therefore thought to result 
from cellular interactions involving the platinum metabolite Pt(dach)Cl2 (Mihara et al. 
2011).  The Pt(dach) complex Pt(dach)Cl2, has been associated with the development of 
oxaliplatin-induced mechanical pain in the late phase; however, it does not appear to 
induce similar oxaliplatin-related symptoms such as cold hyperalgesia (Kawashiri et al. 
2011). The associated mechanical pain following Pt(dach)Cl2 administration is thought to 
result from the neurotoxicity of platinum (Kawashiri et al. 2011). Urinary excretion and 
covalent cellular binding of platinum from blood plasma is believed to be the predominant 
method of platinum elimination in humans (Graham et al. 2000).

Oxaliplatin is known to preferentially accumulate in the dorsal root ganglion, with the 
degree of accumulation correlating with the degree of neuropathic symptom severity 
(Sprowl et al. 2013; Kono et al. 2015). Yonezawa et al. (2011), determined that platinum 
compounds such as cisplatin and oxaliplatin are transported into cells using organic 
cation transporters (OCT). This study involved renal tissue, where oxaliplatin was found to 
be potently transported into kidney cells by OCT2 and weakly by OCT3 receptors 
(Yonezawa et al. 2011). Building upon this work, Sprowl et al. (2013) investigated 
oxaliplatin accumulation in nervous tissues in animals expressing OCT2 in the dorsal root 
ganglion. Increased oxaliplatin accumulation was reported in wild-type animals and those 
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over-expressing OCT2 receptors, with limited oxaliplatin accumulation reported in OCT2-/- 
mice (Sprowl et al. 2013). Sprowl et al. (2013) and Kono et al. (2015) in their investigations 
determined oxaliplatin (platinum) accumulation in rodent nervous tissue using either 
atomic absorption spectroscopy or inductively coupled plasma mass spectrometry (ICP-
MS), respectively. Both techniques, however, fail to provide information about the 
locations within dorsal root ganglia tissue where platinum preferentially accumulates.  



1.5 Oxaliplatin-Induced Peripheral Neuropathies  
With its first introduction into clinical trials in 1986 by Mathé and colleagues, oxaliplatin 
has been known to produce side-effects (Mathé et al. 1986). Since this initial trial, 
additional researchers and clinicians have documented the development of sensory 
proprioceptive peripheral neuropathies in patients of two distinct forms when undergoing 
treatment with oxaliplatin (Canta et al. 2015). Acute oxaliplatin-induced peripheral 
neuropathies are characterised by the development of transient sensory paresthesias 
(tingling) and dysesthesias (unpleasant feeling when touched) predominately in the hands 
and feet; with symptoms typically exacerbated upon exposure to cold temperatures 
(Renn et al. 2011; Tsubaki et al. 2015). The onset of symptoms varies. Roughly 85% of 
individuals experience some level of discomfort, with a large portion of these reporting 
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Oxaliplatin
Oxalate
Pt(dach)Cl2
Figure 1.4.1. Example of the biotransformation of oxaliplatin via a non-enzymatic process producing two 
degradation products: oxalate and the Pt-dach complex, Pt(dach)Cl2
symptom development within hours of drug exposure (Tsubaki et al. 2015). Acute 
symptom development is transient, lasting anywhere from a few hours to a few days 
(Carozzi et al. 2015) and largely resolving between drug administration cycles (Di Cesare 
Mannelli et al. 2013). However, symptom duration may increase with repeated 
administration (Carozzi et al. 2015). While acute peripheral neuropathies are distressing, 
the major dose-limiting complications of the drug result from the development of chronic 
oxaliplatin-induced neuropathic pain. Symptoms are similar to those seen with cisplatin, 
apart form ototoxicity, largely manifesting as prolonged sensory disturbances in the 
extremities.  Symptoms typically include sensory ataxia and deficits in motor coordination 
and the development of non-cold related dysesthesias and paresthesias (Saif & Reardon 
2005; Park et al. 2015). Chronic neuropathic signs tend to persist between drug 
administration cycles, and sometimes for months or years following chemotherapy 
cessation (Saif & Reardon 2005).

1.5.1 Ion Channel Modulation and Neuropathic Pain  
One of the earliest symptoms to develop in both humans and rodents upon administration 
of oxaliplatin is a cold hypersensitivity. In blood plasma, oxaliplatin undergoes non-
enzymatic conversion to oxalate and dichloro(1,2-diaminocyclohexane) platinum(II) 
(Pt(dach)Cl2). The former biotransformation product is able to rapidly chelate Ca2+ ions 
(Grolleau et al. 2001) disrupting Na+ ion-channels in nervous tissue (Argyriou et al. 2015; 
Carozzi et al. 2015). Studies have shown that following administration of oxalate, cold 
hypersensitivity symptoms rapidly develop in rodent models (Sakurai et al. 2009; Zhao et 
al. 2012). This has been explained in part by the action of oxalate on nervous tissues, 
particularly neuronal voltage-gated sodium ions channels where it promotes a prolonged 
open state and hyper excitability of DRG neurons (Carozzi et al. 2015). Other studies have 
shown that oxaliplatin- and oxalate-induced cold hypersensitivities could be negated 
following the addition of Ca2+ and Mg2+ ions (Grolleau et al. 2001; Webster et al. 2005). 
Furthermore, oxaliplatin-induced cold hypersensitivities in the acute and chronic phase 
have been partially explained following the contribution of non-selection transient 
receptor potential (TRP) cation channels. Transient receptor potential ankyrin 1 (TRPA1) is 
activated by adversely cold temperatures (<10oC) and are localised in dorsal root ganglion 
sensory neurons (Park et al. 2015). Zhao et al. (2012) demonstrated that oxalate and 
oxaliplatin was able to enhance the responsiveness of TRPA1 channels and nocifensive 
behaviour to cold following a single intraperitoneal injection. Similarly, enhanced 
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sensitisation of TRP Vallinoid 1 (TRPV1) (Anand et al. 2010) and TRP melastatin (TRPM8) 
(Descoeur et al. 2011) has been observed in oxaliplatin-treated dorsal root ganglion cells, 
where they convey information about noxious heat and cold-temperatures, respectively 
(Bautista et al. 2007; Elokely et al. 2015). Neurobiological studies have demonstrated that 
these channels play a consequential role in the development of thermal and mechanical 
hypersensitivities following peripheral nerve injury induced by oxaliplatin and other 
chemotherapeutics (Chukyo et al. 2018). However, the pathophysiology of chemotherapy-
induced peripheral neuropathies is likely to be multifactorial and not limited to the 
contribution of specific ion channels.

1.5.2 Contribution of Glia to Neuropathic Pain 
Neuroglia, simply referred to as glia, may be involved in the development and 
maintenance of pain associated with chemotherapeutics (Di Cesare Mannelli et al. 2013; 
Boyette-Davis et al. 2015). Glia broadly comprises two classes, macroglia consisting of 
astrocytes and oligodendrocytes, and microglia (Glees 1956). Until recently, astrocytes 
were considered passive cells, maintaining homeostasis for synaptic neurons in the 
central nervous system and acting largely as supportive cells (Tembruni & Jacob 2001). 
However, there is increasing evidence supporting claims that astrocytes command more 
active roles within the nervous system. Protoplasmic astrocytes are found within grey 
matter and fibrillary astrocytes within white matter; each ensheath blood vessels, 
however, protoplasmic astrocytes additionally enclose synapses and fibrillary astrocytes 
contact nodes of Ranvier (Barres 2008). All roles of astrocytes are not understood; they 
extend thousand of processes throughout the neuropil forming a dense network and 
contain receptors for a variety of neurotransmitters (Barres 2008). Astrocytes release 
numerous neuroactive substances, as well as trophic factors, although much of their roles 
remain a mystery. However, it is generally accepted that these cells play important roles in 
the development and physiology of the central nervous system (Barres 2008; Araque & 
Navarette 2010). Apart from normal cellular function within the CNS, astrocytes have been 
implicated in disease states. As astrocytes constitute more than half the cells in the 
human brain, there is no neurological disease devoid of astrocyte involvement (Barres 
2008). Reactive astrocytes up-regulate synapse-inducing genes which have the potential 
to repair the brain, however, they may also be implicated in the development of 
neuropathic pain by inducing unwanted synapse formation (Barres 2008). Astrocyte 
activity is suspected of contributing to oxaliplatin-induced neuropathic pain. Within the 
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brain, notably the ventroposterolateral nucleus of the thalamus and anterior cingulate 
gyrus, Di Cesare Mannelli et al. (2013) observed increased astrocyte expression by way of 
immunohistochemistry, which was concurrent with a reduced threshold for mechanical 
and cold-thermal stimuli. Similarly, altered astrocyte expression has been reported in the 
spinal cord of oxaliplatin-treated rodents coincident with the development of pain states 
(Ahn et al. 2014; Robinson et al. 2014; Jung et al. 2017). Investigations which limited the 
expression of spinal astrocytes following oxaliplatin administration with either minocycline 
(Boyette-Davis & Dougherty 2011; Robinson et al. 2014; Di Cesare Mannelli et al. 2017), 
carbenoxolone (Carozzi et al. 2015) or traditional Chinese medicine herbal extracts (Di 
Cesare Mannelli et al. 2017; Jung et al. 2017) reported reduced oxaliplatin-related 
neuropathic pain symptoms, thereby supporting astrocyte involvement in chemotherapy-
induce peripheral neuropathies (CIPN).  

There is competing evidence, however, for the participation of microglia in oxaliplatin-
induced peripheral neuropathies. Although glia are believed to contribute to CIPN, 
Robinson et al. (2014) propose that only astrocyte activity is related to the pain state 
associated with oxaliplatin. Microglia activity, however, did not appear to be explicitly 
investigated following oxaliplatin treatments in the study by Robinson et al. (2014); with a 
lack of microglia involvement in sensory neuropathies instead being inferred from an 
investigation involving bortezomib. Bortezomib is a non-platinum based therapeutic 
proteasome inhibitor known to produce a small fibre peripheral neuropathy of ill-defined 
aetiology (Argyriou et al. 2008). Other investigations have, however, described microglia 
involvement in oxaliplatin pain, at least transiently (Ahn et al. 2014). Microglia are the 
resident immune cells of the central nervous system, able to patrol the microenvironment 
and respond to pathogens and damage (Soulet & Rivest 2008; Yin et al. 2017). Microglia 
activity is tightly controlled by the CNS microenvironment, with mounting evidence 
suggesting that disturbances within the CNS could change microglia activity and function 
(Perry & Teeling 2013). Microglia regulate CNS homeostasis by coordinating immune 
responses in the presence of inflammatory or pathological stresses; while their 
dysregulation has been linked with the development of CNS disorders (Yin et al. 2017). 
Even in their presumed ‘resting’ state, new evidence suggests that microglia are vigilant 
housekeepers, patrolling the microenvironment with motile processes (Nimmerjahn et al. 
2005). Following peripheral nerve injury, microglia become activated and undergo rapid 
phenotypic changes; shortening their processes and decreasing their complexity (Di 
Cesare Mannelli et al. 2017; Inoue & Tsuda 2018). Numbers of spinal dorsal horn microglia 
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are increased several days after peripheral nerve injury, a process referred to as 
microgliosis ( Inoue & Tsuda 2018). Following oxaliplatin administration, 
immunohistochemistry techniques have revealed increased levels of brain and spinal 
microglia populations (Di Cesare Mannelli 2013; Di Cesare Mannelli 2014; Jung et al. 
2017). Additional studies involving other chemotherapeutics have supported the 
involvement of microglia in the development of CIPN (Burgos 2012). 

Peripheral nerve injury may recruit microglia and astrocyte involvement in oxaliplatin-
induced neuropathies following afferent nerve damage by the release of pro-inflammatory 
mediators such as cytokines and interleukins into the neuropil (Inoue & Tsuda 2018). 
Whether this involvement of glia is a result of platinum accumulation in the CNS and PNS 
from the Pt(dach) carrier ligand Pt(dach)Cl2 and oxaliplatin remains to be explored.  

1.6 Introduction to Scanning Electron Microscopy     
Scanning electron microscopy (SEM) is a powerful technique for obtaining high-resolution 
images of distinct structural features in both organic and inorganic samples. In electron 
microscopy analysis, details about sample structure, dimensional topography and 
elemental composition are obtained following bombardment of the sample surface by an 
accelerated electron beam in vacuum (Fischer et al. 2012). This primary incident beam of 
electrons is formed (in reference to the instrumentation used in this study) by a tungsten-
wire filament electron gun. Electrons are subsequently accelerated towards an anode 
before passing through one or more electron condensers and lenses (Nixon 1971), fig. 
1.6.1. The electron beam is then deflected by a Controlled Scanning Generator which 
ensures the electron beam is moved across the sample in a predetermined manner (Nixon 
1971). This is called the raster. The beam of electrons interact with the surface of a 
specimen through a variety of physical processes collectively termed ‘Scattering 
Events’ (Goldstein 2003). Several detectors positioned around the electron gun detect 
different scattered electrons that leave the sample surface. Commonly used scattered 
events for the formation of an image are Secondary Electrons and Backscattered 
Electrons.

1.6.1 Secondary Electrons and Image Formation  
Secondary electrons are created when the primary electron beam interacts with a sample 
causing some electrons to lose energy in a phenomenon known as inelastic scattering 
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(Robinson 1974). When the incident beam of primary electrons strikes a sample, weakly 
bound valence electrons from the surface of the sample are ejected and subsequently 
detected (Moncrieff & Barker 1978; Goldstein 2003). These low energy electrons (~<50eV) 
are formed along the entire path of the beam electrons through the sample. However, only 
those formed near the surface of specimen have enough energy to escape as their low 
kinetic energy prohibits deeper electrons from reaching the surface (Goldstein 2003). 
Because only surface secondary electrons are able to be ejected as a result of an 
interaction with the primary electron beam, they carry details about the topography of the 
specimen. Therefore, they are typically used for imaging the surfaces of samples in the 
SEM (Bauer 1972; Seiler 1983).
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 Figure 1.6.1. Simplified schematic representation of a Scanning Electron Microscope.
Sample
1.6.2 Backscattered Electrons and Image Formation 
Backscattered electrons (BSE), as their name suggests, are electrons that are ejected 
from the specimen surface (or back-scattered) when the incident primary electron beam 
strikes the specimen (Lager & Raborar 2012). Backscattered electrons are different form 
secondary electrons despite both being emitted from the sample, in fact, the former can 
produce secondary electrons (Bauer 1972; Robinson 1974). Unlike secondary electrons, 
however, backscattered electrons are produced by elastic scattering; they lose little 
energy, sometimes maintaining energies as high as the primary electron beam (Napchan 
2011) as they are deflected by the strong Coulomb field of an atomic nucleus back 
towards the primary beam (Lloyd 1987). Backscattered electrons reveal features deep 
within the sample since these high-energy electrons are not absorbed as easily as lower 
energy secondary electrons (Richards & Gwynn 1995). BSE are detected using a 
backscatter detector positioned around the primary electron beam. Backscattered 
electrons can provide details regarding sample composition, topography and 
crystallography (Goldstein 2003). The detection of backscattered electrons is routinely 
done to highlight contrast in samples. This contrast is a display of different amounts of 
backscattered electrons reaching the detector from different elements and is explained in 
terms of the backscatter electron coefficient and the atomic number, Z. 

The backscatter electron coefficient is defined as: 

η = NBSE / NPB
NPB is the number of electrons from the primary beam that enter the sample with NBSE 
being the number of those electrons that emerge as backscattered electrons. Different 
samples will produce different amounts of backscattered electrons as a result of their 
elemental composition. Experimental measurements utilising the backscattered electron 
coefficient as function of atomic number, Z, have confirmed a monatomic increase in η 
with increasing Z. This relationship provides a basis for atomic number contrast. 
Differences in the elemental composition of a sample can be observed as differences in 
backscatter electron intensity on an SEM image (Goldstein 2003). The fraction of incident 
electrons that generate backscattered electrons (η) increases with atomic number (Z) 
(Lloyd 1987). In a grey-scaled SEM image, this atomic number contrast is observed as 
differences in brightness. Areas containing atoms of high atomic number appear brighter 
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than those areas containing elements of low atomic number as they show a stronger 
signal (Robinson 1980). 
1.6.3 Energy Dispersive Spectroscopy  
Secondary and backscattered electrons are not the only signals given off by a sample 
while it is irradiated with the primary electron beam. Fig. 1.6.3.1 identifies the specimen 
interaction volumes within a sample that encounters an electron beam. That is, the volume 
inside a specimen in which interactions (signal generation) occur while being struck with 
an electron beam. While secondary electrons provide information regarding the surface of 
a sample, and backscattered electrons a crude measurement of sample composition using 
atomic number contrast, neither provides information regarding the exact elemental 
composition of the sample. Characteristic X-rays, which have a greater interaction volume 
than backscattered electrons, can be detected and used to determine the chemical 
distribution within samples. The electron beam of a scanning electron microscope changes 
the initial ground state of atoms, displacing an electron from the K-shell during an inelastic 
scattering event (Goldstein 2003). The ionised atom is left with a vacancy in the K-shell 
which can be replaced by an electron from another electron shell (Goldstein 2003). This 
inter-shell transition energy difference of an element is a sharply defined quantity so that 
the resulting x-ray has an energy that is characteristic of the particular atom species and 
the shells involved and is thus designated as a characteristic x-ray, which are emitted from 
the specimen uniformly and in all directions (Goldstein 2003). In energy dispersive 
spectroscopy (EDS), the characteristic X-rays generated within a sample by electron/
sample interactions are detected to provide information regarding elemental composition 
(Wyroba et al. 2015).  
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 Aims of the Project 
The pathophysiology of chemotherapy-induced peripheral neuropathies is likely 
multifactorial. The broad aim of this investigation was to contribute to the understanding 
of the mechanisms responsible for oxaliplatin-induced neuropathic pain. It was 
hypothesised that platinum accumulates within DRG cells leading to structural disruption 
of the soma and axon (i.e. a form of peripheral nerve injury) which could potentially result 
in microglia and astrocyte activation in the spinal cord dorsal horn. Foundational to this, 
oxaliplatin and Pt(dach)Cl2 were administered intraperitoneally and the rodents subjected 
to behavioural measures to investigate the potential of these drugs to cause neuropathy. 
The main aim of this study, however, was the development and application of a novel 
methodology to investigate platinum accumulation in rodent dorsal root ganglia in order 
to understand platinum-DRG interactions and pain development. This was followed by 
immunohistochemical and histologic tissue analysis to reveal the contributions, if any, of 
glia and nervous tissue alterations in symptom development.
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Figure 1.6.3.1. Interaction volume of the primary electron beam on a sample and the corresponding area 
within a sample where signal electrons and X-rays originate. 
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CHAPTER 2  
METHODS
2.1 Animals and Drug Treatment  
For this project, male (n=18) and female (n=3) Long-Evans rats were randomly allocated 
to treatment or control groups of seven animals each, (Table 2.1). Oxaliplatin and 
Pt(dach)Cl2 were dissolved in 0.9% normal saline (Merck, Australia) by vortex mixing on 
each day of injection. One group of animals were given intraperitoneal injections of 
oxaliplatin ((1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O’)platinum(II)) (Sapphire 
Biosciences, Australia, Cat# 000-13270) (2.5mg/kg) on days 1, 4, 7 and 10 for a total of 
four injections with a final volume of 10mg/kg. Similarly, another group received 
intraperitoneal injections of Pt(dach)Cl2 (Dichloro (1,2-diaminocyclohexane)platinum(II)) 
(Sigma-Aldrich) (2.39 mg/kg) on days 1, 4, 7, and 10 totalling four injections with a final 
volume of 9.56 mg/kg. Control animals received no injection. All injections were 
performed by someone not involved in behavioural analysis. Prior to drug injection, 
animals were anaesthetised in 5% isoflurane and observed after drug administration for 
deviant behaviour. Animals were kept in independently ventilated cages of either 2, 3 or 4 
occupants where they had continuous access to food and water ad libitum. Animals were 
weighed prior to behavioural testing and checked for signs of toxicity. Any animal 
showing signs of distress were immediately and painlessly euthanised. The local ethics 
committee approved the work. Ethics approval number for Western Sydney University: 
A11743 

2.2 Behavioural Testing  
Tests for mechanical pain hypersensitivity, cold-thermal hypersensitivity and heat-thermal 
hypersensitivity were conducted before drug treatment to give a base-line measurement. 
Blinded behavioural testing was conducted following drug treatment for a total of 12 days 
as outlined in Table 2.2.  
2.2.1 Mechanical Allodynia Assessment 
On days 2, 5, 8 and 11 animals were individually weighed before being placed in 10 x 
20cm plexiglass boxes over a wire-mesh floor 20 cm above the bench and allowed to 
habituate for 15 minutes prior to testing. An electronic dynamic plantar aesthesiometer 
(Ugo Basile, France) was used to assess the development of mechanical allodynia in 
rodents. This apparatus applies a von Frey filament (0.5 mm) to the plantar surface of the 
hind paw with increasing force until the paw withdrawal threshold is reached. For this 
experiment a maximal force of 50g was incrementally applied over a duration of 10 
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seconds. The paw withdrawal threshold was defined as the minimum force required to 
elicit an immediate flexion withdrawal response. A cut-off of 10 seconds (or 50g of 
pressure) was implemented to avoid tissue damage. Voluntary movements associated 
with locomotion or grooming were not considered to be a response to the stimulus. 
Animals were allowed to rest for at least one minute between each test to avoid inducing 
sensitisation. The test was performed five times for each animal, with left and right paws 
alternating.



-    -28
Animal I.D. Sex Treatment Group
1502 M
Control
1506 M
1507 M
1508 M
1608 M
1613 M
1618 M
1510 M
Oxaliplatin (2.5 mg/kg)
1511 M
1512 M
1606 M
1607 M
1616 M
1617 M
1528 M
Pt(dach)Cl2 (2.39 mg/kg)
1529 M
1532 F
1533 F
1534 F
1611 M
1612 M
Table 2.1  Animal allocation for investigation              
 2.2.2 Heat-thermal Hypersensitivity Assessment 
The Hargreaves test is used to quantify heat thresholds for rodents by applying a radiant 
or infrared heat stimulus to the plantar surface of the hind paw (Hargreaves 1988). For this 
experiment, animals were placed in 10 x 20 cm plexiglass boxes with plexiglass floors 
which were suspended 12 cm above the bench. Animals were tested for heat sensitivity 
on days 2, 5, 8 and 11, and typically followed mechanical allodynia assessment. Animals 
were allowed to habituate for 15 minutes prior to testing. Using a Hargreaves Apparatus 
(Ugo Basile, France) an infra-red beam set at 90% intensity was positioned underneath 
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DAY DATE ACTIVITY
- 09.02.2018 Training Day - Mechanical / Heat
- 10.02.2018 Training Day - Cold Thermal
- 12.02.2018 Training Day - Mechanical / Heat
- 13.02.2018 Training Day - Cold Thermal
- 15.02.2018 Training Day - Mechanical / Heat
- 16.02.2018 Training Day - Cold Thermal
1 17.02.2018 Injection 1 
2 18.02.2018 Behaviour - Mechanical / Heat 
3 19.02.2018 Behaviour - Cold Thermal 
4 20.02.2018 Injection 2
5 21.02.2018 Behaviour - Mechanical / Heat 
6 22.02.2018 Behaviour - Cold Thermal 
7 23.02.2018 Injection 3 
8 24.02.2018 Behaviour - Mechanical / Heat 
9 25.02.2018 Behaviour - Cold Thermal 
10 26.02.2018 Injection 4
11 27.02.2018 Behaviour - Mechanical / Heat 
12 28.02.2018 Behaviour - Cold Thermal 
13 01.03.2018 Animal Sacrifice
Table 2.2  Training, injection and behavioural testing timetable for the investigation             
the animals and applied to the plantar surface of the hind paws. Heat sensitivity threshold 
was defined as the minimum time taken to elicit a distinct and immediate withdrawal of 
the stimulated paw. A cut-off time of ten-seconds was used to avoid tissue damage. Both 
left and right paws were tested with each test alternating between the paws. A resting 
period of at least one minute was introduced to avoid tissue damage and sensitisation of 
the area. Each test was conducted five times and results averaged 

2.2.3 Cold-thermal Hypersensitivity Assessment  
The cold plate assay is a  simple and relatively accurate method to measure behavioural 
responses to noxious and innocuous cold temperatures in rodents (Deuis et al. 2017). In 
this investigation, a cold plate was used to assess the development of cold-induced 
hypersensitivity symptoms on days 3, 6, 9 and 12. Prior to testing, rodents were 
individually weighed and checked for signs of distress before being placed onto a cold 
plate (Bioseb, France) kept at 25oC and allowed to habituate for 15 minutes. Two rodents 
were tested simultaneously, each on a seperate plexiglass enclosed cold plate measuring 
16 x 16 cm, and were separated from one another by a StyrofoamTM wall. All tests were 
video-recorded. Testing commenced with the cold plate at 25oC followed by a gradual 
reduction of 2oC every two minutes until reaching 0oC. At each 2oC interval, the behaviour 
of the rat was observed and any signs of cold-induced hypersensitivity recorded. If a rat 
experienced severe distress the test was suspended and the cold-plate allowed to return 
to 25oC before transferring the rat back to its enclosure. Pain-related behaviour was 
observed as either lack of grooming, reduced exploring, wall climbing, guarding of the 
affected limb/s, tail sitting, vocalisations, shaking, paw lifting and jumping (Deuis et al. 
2017). The temperature that these signs first manifested was recorded. 

2.3 Animal Sacrifice and Tissue Harvesting  
After the last behavioural test session, all animals were sacrificed by way of 5% isoflurane 
inhalation (Veterinary Companies Australia, Australia; active ingredient: isoflurane 1ml/ml) 
and LethobarbTM injection (Virbac, Australia; containing active ingredient of 325 mg 
pentobarbitone sodium). Deeply anaesthetised animals were placed on a dissecting rack 
and transcardially perfused with 0.9% normal saline solution following standard perfusion 
techniques (Gage et al. 2012). With the clearing of the liver, which is a good indicator of 
correct perfusion (Gage et al. 2012), the rodent was perfused with 4% paraformaldehyde 
(PFA) (Sigma-Aldrich, Germany) until the animal was completely rigid (~300ml). 
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For 14 of the 21 test animals, brain, spinal cord and L4-5 dorsal root ganglia were taken 
and stored in 4% paraformaldehyde until analysis at 4oC. The remaining animals which 
were of mixed treatment groups, had their brain, spinal cord and L4-5 dorsal root ganglia 
harvested and flash-frozen in liquid nitrogen. These later animals were perfused with 
0.9% normal saline but not 4% paraformaldehyde. Harvested tissues were stored at 
-80oC until analysis. Trigeminal ganglia, liver, stomach, heart, large and small intestine, 
gastrocnemius muscle and hind-paw glabrous skin from paraformaldehyde perfused 
animals was also collected and stored in 4% PFA in-case further investigations requiring 
them.  

2.4 Immunohistochemistry  
Lumbar spinal cord from control, oxaliplatin- and Pt(dach)Cl2-treated animals were 
harvested and postfixed in 4% paraformaldehyde for at least one week before being 
transferred into 20% sucrose and stored at 4oC. Spinal cord segments were embedded in 
Optimum Cutting Temperature (OCT) medium (Sakura, USA) just prior to sectioning using 
a Leica CM1950 cryostat. The spinal cord was sectioned transversely at a thickness of 
14μm and mounted onto poly-L-lysine (Sigma-Aldrich, USA) coated slides with each 
section separated by at least 42μm. Slides were air-dried for 1 hour at room temperature 
and stored at -80oC until needed. Thawed slides were blocked in 10% normal goat serum 
(NGS) (containing PBS) for 1 hour prior to overnight incubation with the following primary 
antibodies: Alexa Fluor λ488 mouse monoclonal conjugated GFAP for astrocytes (1:1000 
Merck Millipore, Cat#: MAB3402X, containing 20 μl Triton-X (ProPure)); and rabbit anti-
Iba1 for microglia/macrophages (1:1000 Wako Pure Chemical Industries Ltd, Cat#: 
019-19741, containing 20 μl Triton-X). Slides were washed three times in 0.01M PBS 
(Merck, Australia) for 10 minutes each. Slides incubated in rabbit anti-Iba1 were 
subsequently incubated for 2 hours in the following secondary antibody: Alexa Fluor λ594 
Goat anti-rabbit IgG (1:1000, Invitrogen Life Technologies, Ref#: A11012). Sections were 
washed three times in 0.01M PBS for 10 minutes each. After immunostaining, sections 
were cover-slipped using 4,6-diamidino-2-phenylindole (DAPI; Vectashield Hard set, 
Vector Laboratories).
 
2.4.1 Immunohistochemistry Image Acquisition and Analysis 
All sections were viewed using a Zeiss ApoTome.2 microscope and all images taken using 
a Hamamatsu C11440 ORCA-Flash 4.0 camera and viewed with Stereoinvestigator 
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software (Carl Zeiss Microscopy). Images were taken of 4 - 5 stained sections for each 
animal for each antibody stain within one week of immunohistochemistry. 
For analysis, slides containing at least 4 sections of appropriately stained lumbar spinal 
cord sections were imaged at 20x magnification using a λ488 filter for GFAP-stained 
sections and a λ594 filter for Iba1-stained sections. A minimum of 7 images were taken 
with each filter for one spinal cord section commencing at the left dorsal horn and 
concluding at the right dorsal horn. For each section imaged using either λ488 or λ594, an 
identical image was captured to identify cell nuclei using DAPI. Spinal cord sections were 
manually stitched together using MosaicJ and photoshop which were then analysed using 
Image J softwareTM (distributed by Image J). Image J was used to calculate the number of 
immunoreactive cells within the spinal cord sections. Cells were regarded as 
immunoreactive and included in the analysis if they co-expressed either GFAP or Iba1 
antibody and DAPI.  
2.5 Investigating Platinum Accumulation in Rodent DRG
Several well-established techniques were employed in the investigation of platinum within 
rodent nervous tissues. The implementation of scanning electron microscopy (section 
2.5.4 - 2.5.4.3) and secondary ion mass spectrometry (section 2.5.5) was new for research 
involving oxaliplatin. 
2.5.1 Mass Spectrometry 
Harvested spinal cord and dorsal root ganglia not destined for scanning electron 
microscopy analysis or immunohistochemistry were taken from treated and control animals 
without being fixed in 4% paraformaldehyde and flash-frozen in liquid nitrogen. Tissues 
were stored at -80oC until needed. Frozen spinal cord and dorsal root ganglia were 
homogenised for mass spectrometry by first being submerged in liquid nitrogen and 
crushed into a fine powder using a mortar and pestle. For preparation of the analyte for 
mass spectrometry, homogenised tissue was made up to 1 ml with reverse osmosis (RO) 
water and vortex mixed. 100 μl of homogenised tissue stock was added to 500 μl MS 
Grade acetonitrile and subsequently centrifuged at 14000 rpm for 10 minutes at room 
temperature. Following centrifugation, 400 μl of supernatant was carefully removed and 
placed into acetonitrile-cleaned EppendorfTM tubes ready for analysis. 
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Analysis was performed using a Waters Xevo Quadrupole-Time of Flight mass 
spectrometer. Approximately 100 μl of analyte was analysed and spectra obtained for at 
least 5 minutes. The machine was cleaned with 100% acetonitrile between each analysis. 
2.5.2 SEM Biological Sample Preparation 
The ability to visualise structures with high structural acuity is often necessary for 
developing reliable conclusions about functional relationships. To understand the impact 
of oxaliplatin and Pt(dach)Cl2 on nervous tissues, scanning electron microscopy was 
utilised to observe structural changes that may explain functional observations. 

In this investigation, left and right L4-5 dorsal root ganglia (DRG) were removed from 
rodents following completion of the drug treatment regime and fixed in 4% 
paraformaldehyde (4% PFA) for several weeks. Biological samples must be processed to 
dryness before being analysed using a scanning electron microscope otherwise they risk 
being destroyed by the vacuum of the SEM (Fischer 2012). Right L4 dorsal root ganglia 
were taken for SEM analysis where they underwent several washes in 0.1M phosphate 
buffer (pH 7.4) before being lipid-fixed with osmium tetroxide (1%) for 2 hours prior to 
dehydration. Dehydration was carried out by submerging DRG and spinal cord in 
ascending concentrations of ethanol (30%, 50%, 70%, 95%, 100%) and 100% acetone. 
Tissues were embedded in 50% and 75% Spurr resin for an hour followed by 100% Spurr 
resin overnight (10 g ERL 4221 (ProSciTech, Cat# 130322), 6 g DER 732 (ProSciTech, 
Cat# C047), 26 g Nonenyl succinic anhydride (NSA) (ProSciTech, Cat# C059), 0.4 g 
Dimethylaminoethanol (DMAE) (ProSciTech, Cat# 120723). After ~12 hours in resin, DRG 
were transferred into moulds containing fresh 100% Spurr resin and polymerised at 60oC 
for 12 hours. Resin-embedded tissues were subsequently sectioned between 1 and 5 
μms by a glass-blade ultramicrotome (University of Wollongong), and mounted onto 
silicon wafers. 

Biological samples are prone to burning and charging within a scanning electron 
microscope because they ineffectually dissipate the charge generated by the primary 
electron beam (Fischer 2012). This can produce imaging artefacts and irreversibly 
damage the sample. To overcome this, coating samples with a thin layer of conducting 
material, either a metal or carbon, improves the charge dissipation capabilities of the 
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sample. Coating also improves topographical contrast for improved image formation 
using secondary electrons, with carbon providing an excellent coating media for high-
resolution imaging (Fischer 2012). For these reasons, sectioned dorsal root ganglia 
mounted onto silicon wafers were sputter-coated with carbon.

2.5.3 Ultramicrotomy
Resin-embedded dorsal root ganglia were sectioned for scanning electron microscopy 
analysis using a Leica EM UC7 Ultramicrotome (University of Wollongong). For sectioning, 
samples were first trimmed using a Leica EM TRIM2 (University of Wollongong) until 
reaching the middle of the dorsal root ganglia. Resin blocks were further trimmed to 
reduce the overall cutting face using a razor blade under a microscope. Trimmed resin 
blocks were cut at a thickness of 1-5 μm and were collected in a water bath attached to 
the ultramicrotome glass blade. DRG sections were placed onto a cleaned silicon wafer 
by immersion in a water drop using a glass Pasteur pipette. At least five sections, 
separated by 15 μm, were mounted onto the silicon wafer and heat-fixed in an oven at 
80oC for 5 minutes. Completed sections were stored in dust-free containers until needed.  
2.5.4 Scanning electron microscopy analysis   
2.5.4.1 Imaging  
Scanning electron micrographs can display a range of information depending on the 
detector used. In this investigation, secondary electrons and back-scattered electrons 
were detected and utilised to investigate the topography of sectioned dorsal root ganglia 
and to potentially identify the exact locus of platinum in these tissues. Resin-embedded 
carbon-coated silicon-mounted dorsal root ganglia obtained from treated and control 
animals were imaged using a Zeiss Merlin VP Compact scanning electron microscope. 
Secondary and backscatter generated images were captured with an accelerating beam 
current of 10 keV. Images of DRG axons were taken at 4000x magnification, while DRG 
cell bodies were imaged in sequence around the perimeter at 1500x magnification. These 
later images were later stitched together using image J software for morphometric 
analysis. Ventral root images were taken at 2500x magnification under the same 
conditions. 
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2.5.4.2 Platinum Analysis 
Scanning electron microscopy micrographs captured using backscattered electron signal 
(BSE) can provide information on the elemental composition of a sample through atomic 
number contrast (Goldstein 2003; Wuhrer et al. 2006). Backscattered electron generated 
images, however, provide non-specific compositional information which can be 
supplemented with energy dispersive X-ray spectroscopy (EDS) analysis. Preliminary 
analysis for platinum distribution in dorsal root ganglia tissue was investigated using 
atomic number contrast on backscattered electron generated images at 15 keV.  Platinum 
should appear brighter than surrounding areas (Robinson 1980). Areas of interest were 
further investigated using a Bruker EDS probe to produce compositional spectra.  

2.5.4.3 X-ray Mapping   
X-ray mapping (XRM) is a useful analytical technique in providing information regarding 
element distribution and abundance as it relates to high magnification sample surface 
images. X-ray mapping is the accumulation of characteristic X-rays produced by 
elements within a sample as they relate to the position of the scanning electron beam on 
a specimen (Wuhrer et al. 2006). X-ray maps are acquired using either EDS or wavelength 
dispersive spectroscopy (WDS) and is particularly useful for the identification of individual 
elements and their distribution within a sample (Wuhrer et al. 2006; Moran & Wuhrer 
2006). For this purpose, X-ray mapping was employed for the detection and distribution 
of platinum within dorsal root ganglia tissue form oxaliplatin- and Pt(dach)Cl2-treated 
animals, a technique has that not previously been used in oxaliplatin related 
investigations. 

Following sample analysis using scanning electron microscopy with EDS probe, it was 
determined that higher resolution was required for platinum detection. Semi-thin (1 µm 
thick) resin-embedded silicon-mounted DRG tissue sections were carbon sputter coated 
to make them conductive for X-ray analysis (Guja et al. 2013) and analysed first using a 
Jeol JXA-8600 with EM probe. Each area of interest was subjected to a 1024 x 1024 full 
spectrum XRM with each point of this map analysed for 50 msec. Element mapping data 
was enhanced by Kernal averaging the X-ray maps and producing individual element 
Quantification maps.
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Samples were then analysed under a lower beam current using a Jeol 7001 with EDS 
probe. Similarly, semi-thin (1 µm thick) resin-embedded DRG sections were mounted onto 
silicon wafers and underwent a 1024 x 1024 (x400 magnification) full spectrum X-ray map 
with each point analysed for 50 msec. Maps were collected for carbon (C), oxygen (O), 
silicon, (Si), chlorine (Cl), platinum (Pt), osmium (Os), sodium (Na), phosphorus (P), and 
calcium (Ca). Full spectrum mapping was performed in which each pixel of an image 
produces a spectrum and is saved for future analysis (Wuhrer et al. 2006). Element 
mapping data was enhanced by Kernal averaging the X-ray maps and producing 
individual element Quantification maps.

Semi-thin tissue sample analysis was followed by XRM of the whole resin block from 
which these samples were sectioned. For this, the DRG resin block was mounted onto an 
aluminium SEM stub with the cut portion exposed to the electron beam. This was 
performed to overcome limitations of the semi-thin sections, in which the interaction 
volume of the primary electron beam exceeded the thickness of the section. It was hoped 
that by analysing the tissue within the resin block, platinum that would otherwise be 
overlooked could be detected. 

X-ray maps are typically gray-scale images. However, the use of colour can enhance the 
visibility of elements of interest. Pseudo-colouring is where a colour (blue, red or green) is 
assigned to a specific element in order to generate a false-colour image of the sample 
(Wuhrer et al. 2006). It is a useful technique for revealing further information regarding 
sample composition and element distribution, as well as elemental associations (Wuhrer 
et al. 2006). Because a single colour, either blue, red or green is assigned to a specific 
element, different elemental associations can be inferred from a single pseudo-colour 
image by appearing as colours that lie between red, blue and green on a spectrum. All full 
spectrum XRM’s after additional quantification were processed for pseudo-colour in an 
effort to enhance the visibility of any detected platinum within dorsal root ganglia tissue.  

2.5.5 Secondary Ion Mass Spectrometry (SIMS)  
SIMS is based on the irradiation of sample surfaces with ions, and the reconstruction of 
an image by taking into account the spatial origins of generated secondary ions (Wirtz et 
al. 2015). SIMS can be utilised to record mass spectra, generate images, and depth 
profiling giving access to elemental and molecular information. In this investigation, semi-
thin (1-5 µm) resin embedded dorsal root ganglion sections were mounted onto cleaned 
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silicon wafers following ultramicrotome preparation. Samples were left uncoated and were 
studied using a Cameca IMS 5FE7 Secondary Ion Mass Spectrometer. Samples were 
analysed using negative caesium ions with a beam impact energy of 15 keV, and a beam 
current of 20pa. On average, 5 seperate areas were examined for each DRG section. 
These areas were chosen at random to include DRG axons and cell bodies with six SIMS 
analysis cycles being performed at each location. The following elements: H-, 14N-, 16O-, 
12C-, 12C- 14N-, 35Cl-, 192Os, 195Pt-, 195Pt 35Cl- were analysed during each cycle for 80 
seconds/element. The raster scan size for each area of interest was initially set at 150 x 
150 μm2 and was used for 3 analysis cycles. Additionally a raster scan size of 75 x 75 
μm2 was used for subsequent analysis of the sample (3 cycles) at the same areas of 
interest as the initial analysis. Computer generated SIMS images were obtained for each 
element at each DRG location for all samples. 

2.5.6 Morphometric Analysis  
Studies evaluating oxaliplatin have implicated multinucleolated and eccentric nuclei and 
nucleoli as signs of neurotoxicity (Holmes et al. 1998). Nucleolar, nuclear and cellular 
dimensions of semi-thin L4-5 dorsal root ganglia sections were measured using a method 
adapted from Tomiwa et al. (1986). Sectioned dorsal root ganglia were imaged at 1500x 
magnification using a Zeiss Merlin VP Compact scanning electron microscope. Between 
100 and 150 cells were measured from each animal across multiple sections (n = 4) which 
were separated by at least 30 μm to avoid measuring the same cell. When more than one 
nucleolus was visible, the largest was measured. Cell body, nucleus and nucleolus 
diameter were measured using Image J software. Eccentricity of the nucleus was identified 
when its centre was in the outer half of the radius of the cell body. Similarly, eccentricity of 
the nucleolus was defined when its centre (or that of the largest) was in the outer half of 
the radius of the nucleus. The results were expressed as a percentage of those cells with 
a visible nucleus and nucleolus. 
The G-ratio is regarded as an accurate measure of axonal myelination (Chomiak & Hu 
2009), therefore, imaged dorsal root ganglia axons underwent G-ratio measurement. 
Sectioned resin-embedded DRGs were imaged at 4000x magnification within the dorsal 
root ganglia, with at least five images being captured for G-ratio measurement which was 
calculated using the following formula adapted from Tsutsumi et al. (2014):
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100 axons were measured at random throughout the dorsal root ganglia for each of  the 
animals using Image J software. Also measured were axons from the ventral root which 
lies anterior to the dorsal root ganglion and was embedded in resin still attached to the 
DRG and sectioned within it. Images were taken using a Zeiss Merlin VP CompSEM at 
2500x magnification and 50 axons were measured for G-ratio from each animal. In total 
8400 seperate measurements were made for G-ratio analysis (DRG and ventral root), 
while 2100 nerve axons were analysed in total. 

Additionally, axons were categorised based on their degree of damage into either non-
damaged, mild: limited structural damage to one section of the nerve axon, moderate: 
progressively worse structural damage in multiple sections of the nerve axon and severe; 
complete myelin detachment and other significant structural damage. Between 250 and 
350 DRG axons were examined per animal with another 250 - 350 axons examined from 
the ventral root for each animal. Axons were examined using high-resolution SEM images 
of resin-embedded DRG sections. The number of damaged and non-damaged axons 
were expressed as a percentage of all examined axons for each animal. These results 
were then averaged to obtain a representation of damaged and non-damaged DRG and 
ventral root axons per treatment group.

C-nociceptive fibres (C-fibres) convey information regarding noxious mechanical, thermal 
and chemical stimuli to the CNS (Dubin & Patapoutin 2010). They are small diameter, 
unmyelinated axons and run through dorsal root ganglia towards the CNS. Due to their 
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functional significance, high-magnification (x4000) scanning electron micrographs were 
taken of DRG tissue sections in order to measure C-fibre area. Fifty C-fibres were 
measured for each treatment group and the area calculated using Image J software. 

2.6 Statistical Analysis 
Data for weight, behaviour, morphometry and immunohistochemistry are presented as 
mean ± standard error of the mean (SEM). For morphometry measurements, the 
differences between mean were analysed using one-way analysis of variance (ANOVA) 
Kruskal-Wallis statistical test followed by Dunn’s multiple comparisons test. Results were 
considered statistically significant at P < 0.05. Behavioural measures were assessed using 
ordinary two-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons 
test.  
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CHAPTER 3  
RESULTS
3.1 Effects of Oxaliplatin & Pt(dach)Cl2 on Animal Weight 
21 Long-Evans rats were separated into three groups with those in the drug treatment 
groups receiving either oxaliplatin (2.5 mg/kg) (n=7) or Pt(dach)Cl2 (2.39 mg/kg) (n=7) and 
the remainder acting as controls. Animals were weighed at the beginning of each testing 
cycle and assessed for signs of distress. Rodents within the treatment groups received 
four intraperitoneal drug injections every three days following behavioural training. During 
the experiment, three animals receiving oxaliplatin were excluded from behavioural 
testing; one animal succumbing to the drug after the first injection and the others 
expressing significant decreases in weight (7 - 10%) after the second injection. The later 
animals also displayed a clear lack of grooming and roaming behaviour prior to 
euthanasia. All animals that showed negative behaviour signs were humanely euthanised 
and their tissues collected for further analysis. The remaining animals receiving oxaliplatin 
showed no signs of suffering nor any significant decrease in weight during the 
experiment, fig. 3.1.1. There were no significant decrease in weight at any time-point for 
animals that received Pt(dach)Cl2 (2.39 mg/kg). Similarly, control animal weight remained 
constant throughout the experiment and all Pt(dach)Cl2 and control animals behaved 
normally thought out the training and behavioural testing periods. All animals that 
completed behavioural assessment showed no obvious signs of discomfort during the 
experiment.
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Figure 3.1.1.  Mean ± SEM weight of animals within control, oxaliplatin- and Pt(dach)Cl2- treatment groups during 
training (•••) and behavioural testing (day 2 - 12). Animals were injected on days 1, 4, 7, and 10 (▼). This data 
excludes those animals that were euthanised prematurely. Control n=7, oxaliplatin n=4, Pt(dach)Cl2 n=7.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
3.2 Behavioural Assessment  
The response to a noxious thermal stimulus was assessed by the Hargreaves thermal 
infrared (IR) assay. Before the first oxaliplatin or Pt(dach)Cl2 injection, there were no 
significant differences in response time during the thermal IR assay amongst the three 
groups, fig 3.2.1(a) (control: 7.4, oxaliplatin: 7.6, Pt(dach)Cl2: 7.8 seconds). In the 
oxaliplatin (2.5 mg/kg) group, the latency of the paw withdrawal response from the 
thermal IR test had significantly increased compared with the control group on Day 5 
(control=7.02, oxaliplatin=10.3) (p < 0.05, fig. 3.2.1a, n=4). However, by Day 8 withdrawal 
latency had returned to pre-injection levels for oxaliplatin treated rodents (7.7 seconds). 
Similarly, Pt(dach)Cl2 significantly increased withdrawal response latency to thermal heat 
on Day 11 when compared with the control (p < 0.01, n=7) and oxaliplatin treatment 
groups (p < 0.05). Overall, however, there were no significant differences between 
treatment and control groups during the thermal IR test for thermal hyperalgesia. 

The withdrawal threshold to a noxious mechanical stimulus was measured by the 
electronic von Frey assay. Withdrawal thresholds did not differ significantly between the 
control and drug-treatment groups during the training period. At no time point following 
drug administration where there any significant differences in paw withdrawal threshold 
(grams) between the control (18.6 g), oxaliplatin (24 g) and Pt(dach)Cl2-treatment groups 
(21.1 g). However, on day 5, two rats having received two oxaliplatin injections, presented 
with abnormal behaviour and reduced weight. Assessment of these rodents for both 
mechanical and heat sensitivity found them to be completely unresponsive to either 
stimulus, even when approaching the test cut-off limits (50g von Frey and 15 sec 90% IR 
intensity). These animals were subsequently euthanised.

Neither oxaliplatin nor Pt(dach)Cl2 produced cold-related hypersensitivity behaviour at any 
temperature used throughout the cold-plate assay at any time point. 
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Figure 3.2.1  Behavioural measures. A: the response to thermal heat stimuli was evaluated by the Hargreaves IR 
test measuring the latency (s) to pain-related behaviour (paw withdrawal). B: the response to mechanical sensitivity 
threshold was assessed by electronic von Frey assay measuring the force (g) to pain-related behaviour (paw 
withdrawal). Animals were treated every 3 days with either oxaliplatin (2.5 mg/kg) or with Pt(dach)Cl2 (2.39 mg/kg) 
or received no injection (control). Each value represents the mean ± SEM of n=7 (control), n=4 (oxaliplatin) and n=7 
(Pt(dach)Cl2). Training period: •••. Animals were injected on days 1, 4, 7, and 10 (▼). This data excludes those 
animals that were euthanised prematurely. * P < 0.05, ** P < 0.01.                                                                                                
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3.3 Immunohistochemistry 
Glial activation within the spinal cord was assessed by immunohistochemistry using Iba1 
and GFAP antibodies to examine microglia and astrocyte activity, respectively. In order to 
evaluate microglia activation, the number of Iba1-positive cells in the spinal cord dorsal 
horn of the spinal cord from treatment and control animals was evaluated (6 horns/
animal). Assessment of this region in oxaliplatin- and Pt(dach)Cl2-treated rodents 
following four intraperitoneal drug injections showed no significant differences in the total 
number of Iba1-reactive cells when compared with controls, fig. 3.3.1 and 3.3.3.

Astrocyte activation was measured as an increase in the number of spinal cord dorsal 
horn GFAP-positive cells following oxaliplatin and Pt(dach)Cl2 treatments. GFAP cell 
density was increased in oxaliplatin-treated superficial dorsal horn laminae following four 
intraperitoneal injections when compared with controls, fig. 3.3.2 and fig. 3.3.3 (6 horns/
animal). Pt(dach)Cl2 treatments did not appear to significantly affect the number of GFAP-
expressing cells within the dorsal horn of treated rats when compared with controls, fig. 
3.3.3.
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Figure 3.3.1. Microglia profile in spinal cord dorsal horns. Iba1-positive cells evaluated after four intraperitoneal injections 
of oxaliplatin and Pt(dach)Cl2 over 12 days. Iba1-positive cell nuclei additionally stained with DAPI to confirm labelling of 
microglia (arrows). Microglia density remains largely unchanged across treatment groups (original magnification 20x). Scale 
bar: 100µm.
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Figure 3.3.2. Astrocyte profile in spinal cord dorsal horns. GFAP-positive cells evaluated after four intraperitoneal injections 
of oxaliplatin and Pt(dach)Cl2 over 12 days. GFAP-positive cell nuclei additionally stained with DAPI to confirm labelling of 
astrocytes (arrows) Astrocyte density is increased in oxaliplatin-treated, but not Pt(dach)Cl2-treated, spinal cord sections 
(original magnification 20x). Scale bar: 100µm.
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3.3.3. Evaluation of glial activation after oxaliplatin and Pt(dach)Cl2 treatments. A: Sections of spinal cord 
stained with glial fibrillary acidic protein (GFAP) for evaluation of astrocyte activation. Significant increase in 
astrocyte density in oxaliplatin-treated rodents (Oxa.) compared with controls (Con.) (★ P<0.05). B: Sections of 
spinal cord stained with ionised calcium binding adaptor molecule (Iba1) for evaluation of microglia activation. 
Data are expressed as the mean ± SEM of six dorsal horn/animal (n=5). 
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3.4 Determination of Platinum Accumulation   
To understand the role of dorsal root ganglion platinum accumulation in oxaliplatin-
induced peripheral neuropathies, locations of preferential platinum accumulation were 
investigated in dorsal root ganglia following oxaliplatin and Pt(dach)Cl2 treatments. For 
this undertaking, resin-embedded dorsal root ganglia sections were examined for 
platinum using scanning electron microscopy and full spectrum X-ray mapping analysis.   

3.4.1 Scanning Electron Microscopy Analysis 
Backscattered electron generated images of semi-thin dorsal root ganglia sections were 
used to identify areas that may accumulate platinum based on atomic number contrast. 
Prospective areas were further investigated using electron dispersive spectroscopy (EDS) 
in an effort to discern elemental composition of the area of interest. Platinum was not 
discovered in any of the samples analysed using these methods. 

3.4.2 Full Spectrum X-ray Mapping 
Semi-thin DRG sections were mounted on silicon wafers and carbon-sputter coated for 
X-ray mapping. For each sample, an area corresponding to 1024 x 1024 pixels was 
investigated using a 15 kilo-electronvolt (keV) electron beam voltage, with each point 
analysed with a collection time of 50 msec/pixel. At each pixel, the element composition 
was examined using energy dispersive spectroscopy in order to build a full spectrum X-
ray map of the sample. Mapping was performed using a Jeol JSM-7001F field emission 
scanning electron microscope and Jeol EM probe. 

3.4.2.1 Determination of Platinum in DRG tissue  
Dorsal root ganglia taken from animals known to have received either oxaliplatin or 
Pt(dach)Cl2 were investigated for platinum accumulation sites by way of full spectrum X-
ray mapping. In these investigations, X-ray maps were performed at increasing levels of 
magnification (x300 - x2000) and for only a small number of elements including carbon, 
oxygen, chlorine, osmium, silicon and platinum. For the sample shown in Fig. 3.4.2.1, a 
full spectrum X-ray map was performed at x2000 magnification and centred on a DRG 
axon and included surrounding glial cells and DRG cell bodies. X-ray maps for each 
element were collected and Kernal averaged using Moran Scientific X-ray mapping 
software. Quantification (Quant) maps of each element were then generated from the 
Kernal averaged data, where small, potential areas of platinum were identified, fig. 3.4.2.2 
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(A and B). To confirm the presence of platinum with the DRG section, scatter diagrams 
that depict pixel frequency versus element concentration were plotted against each other 
for platinum/chlorine, platinum/osmium and chlorine/osmium. Clusters representing high 
platinum frequency to either choline or osmium were then matched to the corresponding 
backscatter generated (BSE) SEM image, fig. 3.4.2.3. Platinum was shown to cluster near 
DRG cell body plasma membranes rather than the axon, fig. 3.4.2.3. Pseudo-colouring of 
the BSE image from elemental Quant maps confirmed the presence of platinum adjacent 
to the plasma membrane of DRG cells, fig. 3.4.2.4 - 3.4.2.5. In this analysis, platinum, 
carbon and osmium were assigned a unique colour: red, blue or green, respectively. 
Areas identified as containing platinum in both scatter diagram zone-matched images and 
pseudo-coloured images were quantified for platinum using energy dispersive 
spectroscopy. Obtained spectra presented in fig. 3.4.2.6, confirmed the presence of 
platinum at the largest site identified by the scatter diagrams, producing a distinguishable 
peak at the Lα characteristic X-ray position (9.441 keV). Generated platinum spectra 
peaks were then superimposed over the obtained spectra; these matched closely with the 
sample, confirming the presence of platinum, fig, 3.4.2.6c.   
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Figure 3.4.2.1. Backscattered electron (BSE) generated image of resin-embedded DRG section from an oxaliplatin 
treated animal mounted onto a silicon wafer. Axons (Ax.) are identified by their bright white colour having been fixed 
with osmium. Image captured at x2000 magnification. Scale bar: 5µm. 
Cell bodyAx.
A B
Figure 3.4.2.2. Quantified X-ray maps of a dorsal root ganglion section from an oxaliplatin treated animal representing 
element distribution. A: backscatter electron image (BSE) of DRG section. Additional scatter diagram data 
representing platinum indicated by arrows. B: quantified X-ray map of platinum (Pt). Areas of platinum accumulation 
indicated by white arrows. Arrows represent the same location between images. Brighter areas indicate areas of 
higher element concentration in individual X-ray maps. SEM image at x2000 magnification. Maps collected at 15 keV, 
1024 x 1024 pixel, 50 msec/pixel. Scale bar: 5 µm     
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Figure 3.4.2.3. Resin embedded dorsal root ganglia tissue extracted from an oxaliplatin-treated animal following 
four intraperitoneal drug injections (2.5 mg/kg). A - C: raw scatter diagrams showing platinum/carbon (A), 
platinum/chlorine (B) and chlorine/osmium (C) associations. Blue rectangles represent potential platinum data 
points in both A and B. D: zoning image created by superimposing selected cluster points from scatter diagrams 
(A - C) onto the SEM image. Areas indicated by the white arrows corresponds areas of potential  platinum 
accumulation. SEM image at x2000 magnification. Maps collected at 15 keV, 1024 x 1024 pixel, 50 msec/pixel. 
Scale bar: 5 µm     
A B C
D
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Figure 3.4.2.4. Trichrome pseudo-coloured DRG SEM backscattered electron generated image. The pseudo-coloured 
image is created by quantifying X-rays maps for individual elements and assigning a unique colour to three elements 
of interest. Osmium (Os): blue, Carbon (C): green and Platinum (Pt): red. Areas of potential platinum accumulation 
further identified by arrows. Area indicated by the white square was further magnified in (b). Maps collected at 15 keV, 
1024 x 1024 pixel, 50 msec/pixel. Scale bar: 5 µm    
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Figure 3.4.2.5. Trichrome pseudo-coloured DRG SEM backscattered electron generated image. The pseudo-coloured 
image is created by quantifying X-rays maps for individual elements and assigning a unique colour to three elements 
of interest. Osmium (Os): blue, Carbon (C): red and Platinum (Pt): green. Areas of potential platinum accumulation 
further identified by arrows. Area indicated by the white square was further magnified in (b) Maps collected at 15 keV, 
1024 x 1024 pixel, 50 msec/pixel. Scale bar: 5 µm    
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Figure 3.4.2.6. Energy dispersive spectroscopy (EDS) analysis. Analysed area in (A) (BSE image) indicated by white 
circle. B: obtained spectra. Observable characteristic X-ray at the 9.441 Lα characteristic X-ray location for platinum 
(Pt) C: simulated characteristic X-ray peaks for platinum (black) superimposed over sample generated spectra.   
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3.4.2.2 Determination of Platinum in Resin

Additional X-ray maps were performed on other dorsal root ganglia sections from 
oxaliplatin-treated animals. Utilising atomic number contrast, fig. 3.4.2.7 confirmed the 
presence of a high atomic number element within the resin surrounding the DRG from an 
oxaliplatin-treated animal. A full spectrum X-ray map of the DRG section using an electron 
beam voltage of 15 keV obtained element distribution information for several elements 
including carbon, oxygen, osmium, chlorine, silicon and platinum at x400 magnification. 
Each element map underwent individual Kernal averaging and subsequent quantification 
in order to produce quantitative (Quant) maps of each element, fig. 3.4.2.8. Bright areas 
within each of these Quant maps corresponds to an area containing the element of 
interest, whereas darker areas are lacking in the element. The Quant map of platinum 
shows a large region of platinum accumulation which, when matched to the BSE image, 
is situated within the encasing resin block, fig. 3.4.2.8. Platinum was not found within the 
tissue. To corroborate the presence of platinum at this location within the resin, scatter 
diagrams that depict pixel frequency versus element concentration were plotted against 
each other for platinum/carbon and platinum/chlorine. Clusters representing high 
platinum frequency to either choline or carbon were then matched to the corresponding 
backscatter generated SEM image, fig. 3.4.2.9. Scatter diagram matched areas confirmed 
platinum accumulation in the resin surrounding the DRG tissue. Energy dispersive 
spectroscopy of this region verified the presence of platinum, fig. 3.4.2.10. The obtained 
spectra exhibited a peak at approximately 9.4 keV, which closely matches the Lα 
characteristic X-ray for platinum, fig. 3.4.2.10. Finally, obtained Quant maps for platinum, 
chlorine and carbon were assigned individual colours to produce pseudo-coloured 
element distribution images, fig. 3.4.2.11. These images further confirmed the territory 
within the encasing resin block that contained platinum.  
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Figure 3.4.2.7. Dorsal root ganglia / resin backscattered electron generated image. Bright areas indicate 
areas of high atomic number and darker areas correspond to areas of lower atomic number. Area of potential 
platinum accumulation is indicated by the arrow. Platinum has a high atomic number (78) compared to other 
elements within biological material (e.g. carbon: 6, oxygen: 8) and therefore should appear bright. Scale bar: 
30 µm.  
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Figure 3.4.2.8. A: Backscattered electron (BSE) generated image of a semi-thin (1 μm) dorsal root ganglia 
section inclusive of the resin block. B - F: quantified X-ray maps for carbon, chlorine, oxygen, silicon and 
platinum (arrow indicates site of platinum accumulation). Arrows correspond to the same region across 
images. For individual X-ray maps, brighter regions indicate areas of element accumulation and darker areas 
indicate areas devoid of the element of interest. Scale bar: 30 μm.
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Figure 3.4.2.9. Resin embedded dorsal root ganglia tissue extracted from an oxaliplatin-treated 
animal following four intraperitoneal drug injections (2.5 mg/kg). A - B: raw scatter diagrams 
showing platinum/carbon (A) and platinum/chlorine (B) associations; blue rectangles represent 
potential platinum data points in both A and B. C: zoning image was created by superimposing 
selected cluster points from scatter diagrams (A - B blue rectangles) onto the SEM image. Area 
indicated by the white circle corresponds to platinum as assessed using EDS analysis. Selected 
scatter diagram matched areas indicated by white arrows could not be determined to be sites 
of platinum accumulation using EDS analysis (data not shown). SEM image at x400 
magnification. Maps collected at 15 keV, 1024 x 1024 pixel, 50 msec/pixel (WOF = 258 μm). 
Scale bar: 30 µm     
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Figure 3.4.2.10. Resin embedded semi-thin (5 μm) dorsal root ganglia tissue section extracted 
from an oxaliplatin-treated animal following four intraperitoneal drug injections (2.5 mg/kg). A: 
EDS spectra of the area indicated by the white circle in the pseudo-coloured SEM image (B) 
shows a platinum (Pt) peak corresponding to the Lα characteristic X-ray for platinum (9.441). 
B: pseudo-coloured SEM image; Red: platinum, blue: silicon, green: carbon. Resin is indicated 
by a superimposed orange shading. SEM image at x400 magnification. Maps collected at 15 
keV, 1024 x 1024 pixel, 50 msec/pixel (WOF = 258 μm). Scale bar: 30 µm
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Figure 3.4.2.11. DRG Pseudo-coloured SEM image for carbon (C), chlorine (Cl) and platinum (Pt) 
distribution (uncoloured SEM image represented in figure 3.4.2.8). Colours for carbon and chlorine 
are changed between A and B. Platinum is indicated by red colouring in both images. Maps 
collected at 15 keV, 1024 x 1024 pixel, 50 msec/pixel (x400 mag. WOF = 258 μm). Scale bar: 30 
µm 
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3.4.3 Secondary Ion Mass Spectrometry (SIMS) Analysis  
SIMS is being increasingly utilised in biological and industrial research by offering high 
lateral resolution mass spectra of samples and creating element distribution false-colour 
images of sample surfaces and depth profiling. Platinum accumulation from oxaliplatin- 
and Pt(dach)Cl2 -treatments was investigated in DRG tissue as a complimentary method 
to SEM full-spectrum X-ray mapping. For analysis, 14 animals were administered with 
four intraperitoneal injections of either oxaliplatin or Pt(dach)Cl2 at a comparable clinical 
dose over 12 days. Upon completion of the drug administration phase, animals were 
dissected to obtain L4-5 dorsal root ganglia which were subsequently embedded in resin. 
Semi-thin DRG sections of were mounted onto silicon wafers for analysis by SIMS. For 
each sample, the tissues remained uncoated and were analysed under a caesium ion 
beam with an impact energy of 15 keV. Multiple locations were examined throughout each 
DRG section for determination of distinct platinum accumulation sites. In each analysis, 
carbon (12C), nitrogen (14N), chlorine (35Cl), osmium (192Os) and platinum (195Pt) were 
investigated and used to produce individual secondary ion images of the sample. 
Although several samples appeared to indicate the presence of platinum within DRG 
tissue fig. 3.4.3.2 -3.4.3.8, these points represented a single count registering on the 
SIMS detector and could not be further quantified. Additionally, a similar signal for 
platinum was detected from a DRG section taken from a control animal, fig. 3.4.3.1, 
therefore, platinum was most likely not detected in any of the dorsal root ganglia tissue 
sections from drug-treated animals when the generated false-colour ion images were 
analysed, fig. 3.4.3.1 - 3.4.3.7. Additionally, the resin block surrounding the tissue was 
investigated for platinum from an oxaliplatin-treated animal. Examination of several 
regions across multiple sections failed to detect platinum within the resin, fig. 3.4.3.8. 
Each region of dorsal root ganglia analysed by SIMS underwent 6 analysis cycles.  
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Figure 3.4.3.1. False-colour image of dorsal root ganglion cell bodies from a control animal. A: 12C and 14N ion 
concentration false-colour generated image, with black indicating the lowest concentration and red the highest with a 
visible cell body (solid arrow) containing a nucleus (hollow arrow). B: platinum (195Pt) ion concentration false-colour 
generated image indicating no presence of the element within DRG cell bodies. Arrow indicates an area that generated a 
signal that has been detected and interpreted as platinum by SIMS (count: 1). As this DRG section comes from an animal 
that never received platinum, the data point most likely represents a false-signal. Scale bar: 20 µm. Raster: 150. Caesium 
beam. Cts: counts  
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Figure 3.4.3.2. Generated SIMS ion images of semi-thin (5 μm) silicon mounted dorsal root ganglion sections. A: 
Oxygen ion concentration false-colour generated image showing high counts of oxygen in DRG myelin. B: Carbon/
Nitrogen ion concentration false-colour generated image showing higher carbon/nitrogen ratio in the DRG myelin 
(blue) than axon (black) C: Chlorine ion concentration false-colour generated image displays higher chlorine 
concentrations in the DRG axon and extracellular matrix (blue). D: Osmium ion concentration false-colour generated 
image displays osmium in DRG myelin surrounding axons from osmium tetroxide fixation during processing. E: 
Platinum ion concentration false-colour generated image showing no distinct areas of platinum accumulation (counts 
= 2). Scale bar: 10 μm. Cts: counts
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Figure 3.4.3.3. False-colour images of dorsal root ganglion cell bodies and axons following SIMS analysis. Black 
represents the lowest element ion concentration and red the highest. Arrows correspond to the same area 
between images. A: Oxygen (16O) ion concentration false-colour generated image representing limited ion 
concentration in DRG cell bodies (solid arrows) B: Carbon (12C) and Nitrogen (14N) ion concentration false-
colour generated image with visible cell bodies (solid arrows) and cell nuclei (hollow arrows) C: Chlorine (35Cl) 
ion concentration false-colour generated image. Arrows correspond to the same cell bodies in depicted in ‘B’. 
D: Platinum (195Pt) ion concentration false-colour generated image. Arrows indicate areas that have generated 
a signal that has been detected and interpreted as platinum by SIMS. However, a signal intensity of 1 count (Cts) 
was generated and most likely represents a false-signal. Scale bar: 20 µm. Raster: 150. Caesium beam. Cts: 
counts.
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Figure 3.4.3.4. False-colour images of dorsal root ganglion cell bodies (solid arrow) and axons (hollow arrow) 
following SIMS analysis from oxaliplatin-treated animal. Black represents the lowest element ion concentration 
and red the highest. A: Hydrogen (1H) ion concentration false-colour generated image. B: Oxygen (16O) ion 
concentration false-colour generated image. C: Carbon (12C) and Nitrogen (14N) ion concentration false-colour 
generated image. D: Chlorine (35Cl) ion concentration false-colour generated image. E: Platinum (195Pt) ion 
concentration false-colour generated image. Arrows indicate areas that have generated a signal that has been 
detected and interpreted as platinum by SIMS. However, a signal intensity of 1 count (Cts) was generated and 
most likely represents a false-signal. Scale bar: 20 µm. Raster: 150. Caesium beam. Cts: counts   
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Figure 3.4.3.5. False-colour images of ventral root axons following SIMS analysis from Pt(dach)Cl2-treated 
animal. Black represents the lowest element ion concentration and red the highest. A: Hydrogen (1H) ion 
concentration false-colour generated image map B: Oxygen (16O) ion concentration false-colour generated 
image. C: Carbon (12C) and Nitrogen (14N) ion concentration false-colour generated image D: Chlorine 
(35Cl) ion concentration false-colour generated image E: platinum ion concentration false-colour generated 
image. Scale bar: 20 µm. Raster: 180. Caesium beam. 
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Figure 3.4.3.6. False-colour images of dorsal root ganglion cell bodies and axons following SIMS analysis 
from a Pt(dach)Cl2-treated animal. Black represents the lowest element ion concentration and red the 
highest. A: Chlorine (35Cl) ion concentration false-colour generated image showing higher chlorine 
concentration in DRG cell nucleolus (hollow arrow) when compared to cell body (solid arrow). Arrows 
correspond to the same area across images. B: Carbon (12C) and Nitrogen (14N) ion concentration false-
colour generated image showing higher levels of carbon and nitrogen in DRG cell nucleolus (hollow arrow) 
when compared to cell body (solid arrow) C: platinum (195Pt) ion concentration false-colour generated 
image. Arrows indicate areas that have generated a signal that has been detected and interpreted as 
platinum by SIMS. However, a signal intensity of 1 count (Cts) was generated and most likely represents a 
false-signal. D: Oxygen (16O) ion concentration false-colour generated image representing low ion 
concentration in DRG cell bodies. Scale bar: 20 µm. Raster: 150. Caesium beam. Cts: counts.
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Figure 3.4.3.7. False-colour images of ventral root axon element concentration from oxaliplatin-treated 
animal. Black indicates areas with the lowest concentration and red represents the highest concentration 
areas. A: Hydrogen (1H) ion concentration false-colour generated image. B: Oxygen (16O) ion concentration 
false-colour generated image. C: Carbon (12C) and Nitrogen (14N) ion concentration false-colour generated 
image. D: Chlorine (35Cl) ion concentration false-colour generated image. E: Platinum (195Pt) ion 
concentration false-colour generated image. Arrows indicate areas that have generated a signal that has 
been detected and interpreted as platinum by SIMS. However, a signal intensity of 1 count (Cts) was 
generated and most likely represents a false-signal. Scale bar: 20 µm. Raster: 150 µm. Caesium beam.
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Resin
Resin
Figure 3.4.3.8. Oxaliplatin-treated animal (1607) dorsal root ganglia with resin. A: carbon/nitrogen ion concentration false-
colour generated image. Colour intensity relates to the relative abundance of the element of interest at different sites. Red 
indicating highest concentration and black the lowest. B: oxygen ion concentration false-colour generated image C: chlorine 
ion concentration false-colour generated image. D: platinum ion concentration false-colour generated image. Arrows indicate 
areas that have generated a signal that has been detected and interpreted as platinum by SIMS. However, a signal intensity 
of 1 count (Cts) was generated and most likely represents a false-signal. Caesium beam. Raster 150 µm. Scale bar: 20 µm. 
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3.4.4 Mass Spectrometry  
Prior to drug-treated tissue analysis, oxaliplatin and Pt(dach)Cl2 pure samples were 
analysed using a Waters Xevo QToF mass spectrometer performing electrospray 
ionisation (ESI) analysis to obtain ion spectra of these compounds. Oxaliplatin was 
dissolved in 0.9% normal saline solution prior to intraperitoneal administration for 
rodents. Therefore, samples of oxaliplatin were prepared in saline several days prior to 
mass spectrometry analysis. Obtained spectra for each sample revealed that oxaliplatin 
had degraded into Pt(dach)Cl2 in the days prior to analysis. This was determined by 
generating simulated spectra of entities that could be generated by non-enzymatic 
conversion of the drug in saline solution. The spectra of the compound represented in fig 
3.4.4.1 (labelled Bx) bore the most similarity with that obtained from oxaliplatin and saline. 
This structure matches exactly with that of Pt(dach)Cl2 and therefore confirms that 
oxaliplatin had degraded into Pt(dach)Cl2 spontaneously. Additionally, Pt(dach)Cl2 was 
processed for mass spectrometry by being dissolved in acetonitrile and added to 
homogenised spinal cord to determine whether platinum could be detected within tissue 
samples. 500 ng Pt(dach)Cl2 was added to 100 μL homogenised spinal cord solution and 
500 μL  acetonitrile and centrifuged at 14000 rpm for 10 minutes. The supernatant was 
then removed and analysed. Analysis revealed that Pt(dach)Cl2 was able to be detected 
by mass spectrometry, while also confirming that oxaliplatin had degraded into 
Pt(dach)Cl2 in saline solution. Obtained spectra from the oxaliplatin/saline experiment, fig. 
3.4.4.1a, matched closely with simulated spectra of Pt(dach)Cl2, fig. 3.4.4.1b.

As oxaliplatin had degraded into Pt(dach)Cl2  in saline, it was decided to make up a fresh 
oxaliplatin/Milli-Q water and oxaliplatin/acetonitrile solutions just prior to MS analysis, fig. 
3.4.4.2. This was carried out to compare oxaliplatin spectra with the spectra obtained 
from tissues. For the current investigation involving nervous tissue, flash-frozen excised 
rat spinal cord and DRG tissue were homogenised in liquid nitrogen and prepared for 
mass spectrometry using MS grade acetonitrile. Analysis was performed for five minutes 
for each sample, however, the presence of platinum in either spinal cord or dorsal root 
ganglia was unable to be obtained. DRG and spinal cord samples from oxaliplatin, 
Pt(dach)Cl2 and control animals produced similar mass spectra with the former failing to 
display spectra indicative of platinum, fig. 3.4.4.3.  
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Figure 3.4.4.1. Mass spectra of A: 100μL of 1 μg oxaliplatin in 1 mL 0.9% saline solution added to 1 mL Milli-Q water. B: 
simulated spectra of modelled compound Bx (inset). C: 0.5 μg Pt(dach)Cl2 dissolved in 1 mL Milli-Q water, centrifuged 
and added to 500 μL acetonitrile and added to 1 μL homogenised spinal cord (Spike experiment). * significantly similar to 
spectra reported in A and B. This supports the claim that oxaliplatin non-enzymatically converts to Pt(dach)Cl2  in saline 
solution as the spectra match between oxaliplatin/saline (A) and Pt(dach)Cl2 (C) and the simulated spectra of the 
compound represented by ‘Bx’ which has the same structure as Pt(dach)Cl2.  
Bx
Na+
* *
*
*
*
* *
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Figure 3.4.4.2. Mass spectra of A: spectra of 100μL of 1 μg oxaliplatin in 1 mL Milli-Q water. B: spectra of 100μL of 1 μg 
oxaliplatin in 1 mL acetonitrile. Samples were vortex mixed and centrifuged ay 14000 rpm for 10 mins with the 
supernatant removed and analysed using electrospray ionisation mass spectrometry. 
A
B
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Figure 3.4.4.3. Mass spectra of rat dorsal root ganglia from Pt(dach)Cl2 (A), control (B) and oxaliplatin (C) animals. Tissues 
were flash frozen in liquid nitrogen and homogenised using a mortar and pestle. Samples for mass spectrometry were 
vortex mixed with MS grade acetonitrile and centrifuged at 14000 rpm for 10 mins. Supernatant removed and analysed. 
Spectra are similar for all treatment groups indicative of platinum not being detected within the sample and may be 
beyond the deletion limit of electrospray ionisation mass spectrometry.  
A CB
3.5 Morphometric Analysis  
3.5.1  G-ratio, Diameter and Damage  
There were no significant differences between the oxaliplatin- and Pt(dach)Cl2-treatment 
groups and the control group in regard to the total number of fibres that were assessed 
for damage, size and myelination. The ratio of axon diameter to total fibre diameter was 
calculated to assess myelination and was referred to as the G-ratio. Each axonal G-ratio 
was evaluated from the measured average maximum fibre and axonal diameters and the 
minimal fibre and axonal diameters using Image J software (Tsutsumi et al. 2014). 
Measured fibres were additionally categorised according to their location (dorsal root 
ganglion or ventral root) and whether they were visibly damaged. Comparisons between 
groups found no significant differences in axonal G-ratio in either oxaliplatin- and 
Pt(dach)Cl2-treated animals when compared with controls for both DRG non-damaged 
and ventral root non-damaged axons. Although the G-ratio of damaged axons was 
smaller in both DRG and ventral roots compared with non-damaged fibres, this difference 
is not significant. Additionally, there were no significant differences  in G-ratio between the 
drug treatment groups and controls for damaged DRG and ventral root axons, fig 
3.5.1.3a.  

Comparison of axon diameter across treatment groups revealed that damaged DRG 
axons and ventral root fibres had on average, smaller fibre diameters than non-damaged 
axons, however, this difference was not significant. Axons were defined as damaged 
when the myelin was no longer homogenous and the myelin layers were separating and 
bulging (fig. 3.5.1.1 - 3.5.1.2). Axonal DRG size did not significantly differ among drug 
treatment and control groups for damaged and non-damaged fibre populations, fig.
3.5.1.3b. Comparison of ventral root efferent and dorsal root afferent diameters showed 
that ventral root axons are on average larger than DRG fibres. Comparison of damaged 
fibre diameter from both dorsal and ventral root axons showed no significant differences 
in fibre size between axon populations when compared across treatment groups, fig. 
3.5.1.3b; this was similar for non-damaged fibres.     

Axon integrity was assessed by taking high-magnification backscatter generated images 
of dorsal root ganglia and ventral root axons, Fig. 3.5.1.1 - 3.5.1.2. Oxaliplatin treatments 
slightly increased the number of damaged axons in the DRG when compared with control 
and Pt(dach)Cl2-treatment groups, table 3.5.1.1, however, as a  large proportion of control 
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axons showed signs of damage it is doubtful that myelin deterioration is solely drug-
induced. Results were expressed as a percentage of damaged axons out of all 
categorised fibres in both the DRG and ventral root. The ratio of damaged axons to non-
damaged axons for ventral root fibres across all groups approximates 1:1 (Table 3.5.1.2). 
Similarly, the ratio of non-damaged axons to damaged axons in dorsal root ganglia 
approximates 3:1 for control and Pt(dach)Cl2-treated animals and 2:1 for oxaliplatin-
treated animals. Therefore, it is inconclusive as to whether oxaliplatin or Pt(dach)Cl2 cause 
fibre damage that later results in neuropathy development. 
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Figure 3.5.1.1. DRG axons A: Control DRG axons showing slight damage to some axons (arrows). Visible C-fibres 
indicated by circle B: Oxaliplatin-treated DRG axons displaying possible macrophage invasion and significant 
damage of the axon myelin (stars ★). C: Pt(dach)Cl2-treated DRG axons displaying axon myelin damage (arrows). 
Oxaliplatin and Pt(dach)Cl2-treated DRG show more damage than controls. SEM backscatter generated image. 
x4000 magnification. 10 keV. Scale bar: 2 µm.  
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Figure 3.5.1.2. Ventral root axons A: Control ventral root axons with slight myelin damage (arrows) B: Oxaliplatin-
treated ventral root axons. Damaged axon myelin indicated by stars C: Pt(dach)Cl2-treated ventral root axons. 
Damaged axon myelin indicated by stars (★). Oxaliplatin and Pt(dach)Cl2-treated ventral root myelin sheaths 
show more damage than controls. SEM backscatter generated image. x2500 magnification. 10 keV. Scale bar: 10 
µm.  
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Non-damaged Damaged Non-damaged Damaged
Con. Oxa. Pt. Con. Oxa. Pt. Con. Oxa. Pt. Con. Oxa. Pt.
DRG Ventral root
Con. Oxa. Pt. Con. Oxa. Pt. Con. Oxa. Pt. Con. Oxa. Pt.
Figure 3.5.1.3. A: G-ratio comparison between treatment groups: Con. (control), Oxa. (oxaliplatin), Pt. (Pt(dach)Cl2) when 
axons have been separated into DRG non-damaged and damaged categories and Ventral root non-damaged and damaged 
categorie. Damage was assessed by visual inspection of the axon myelin. The data represent the mean ± SEM of 5 sections/
animal (n=5). B: Axonal diameter comparison between treatment groups: Con. (control), Oxa. (oxaliplatin), Pt. (Pt(dach)Cl2) 
when axons have been separated into DRG non-damaged and damaged categories and Ventral root non-damaged and 
damaged categoriee. Damage was assessed by visual inspection of the axon myelin. The data represent the mean ± SEM of 5 
sections/animal (n=5). No significant differences were found in the G-ratios and axon diameters from damaged axons for both 
DRG and Ventral root groups when controls were compared to oxaliplatin and Pt(dach)Cl2-treatments. The same holds for 
non-damaged axons. Additionally, the G-ratios and axon diameters were not significantly different when damaged and non-
damaged groups were compared for both DRG and Ventral root axons. 
Non-damaged Damaged Non-damaged Damaged
DRG Ventral root
A
B
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Control Oxaliplatin Pt(dach)Cl2
# Damaged 367 397 370
# Non-damaged 1187 830 1273
Total cells 1554 1227 1643
% Damaged fibres 23.6 32.5 22.5
Damaged/Non-damaged DRG Fibre Classification 
Table 3.5.1.1
Control Oxaliplatin Pt(dach)Cl2
# Damaged 847 511 728
# Non-damaged 760 367 800
Total cells 1607 878 1528
% Damaged fibres 52.7 58.2 47.6
Damaged/Non-damaged Ventral Root Fibre Classification 
Table 3.5.1.2
3.5.2 C-fibre Area 
To assess the possibility of C-fibre changes in neuropathy development, C-fibre area was 
measured from 50 axons from each of the treatment groups. Measurements were carried 
out using high-resolution SEM backscatter electron generated images with fibre area 
assessed using Image J software. There were no significant differences in C-fibre area 
between drug treatment and control groups, fig. 3.5.2.1.  
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Figure 3.5.2.1 Mean ± SEM C-fibre area from control (Con) animals and oxaliplatin 
(Oxa.) and Pt(dach)Cl2 (Pt.) treatment groups. n = 50 axons/group (n=4). 
3.5.3 Eccentricity  
Dorsal root ganglia cell body, nuclei and nucleoli diameters were measured for evaluation 
of eccentricity using Image J software. Nuclei and nucleoli were classified as eccentric if 
their centre was in the outer half of the radius of the cell body or nucleus, respectively, 
Fig. 3.4.1.5. Results are presented as a percentage of all cells with a visible nucleus and 
nucleolus, (Table 3.5.3.1). Animals that received intraperitoneal injections of Pt(dach)Cl2 
had an increased percentage of cells with eccentric nuclei (38.63%), when compared with 
the control (27%) and oxaliplatin (31%) groups. Additionally, there were more cells from 
Pt(dach)Cl2-treated dorsal root ganglia that contained multinucleolated nuclei (22%) when 
compared to oxaliplatin (11.4%) and control groups (10.8%), table 3.5.3.1. Similarly, 
Pt(dach)Cl2-treated animals displayed higher numbers of cells with eccentric nucleoli 
when compared with controls. However, this was still lower than those that received 
oxaliplatin, with 74.28% of  analysed DRG cells displaying eccentric nucleoli.  
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Figure 3.5.1.5. DRG cell bodies with evident nuclei and nucleoli. A: DRG semi-thin section from control animal 
displaying a DRG cell body (solid arrow) with nucleus (hollow arrow) and nucleolus (yellow arrow). B: DRG section 
form oxaliplatin-treated animal displaying eccentric nucleoli (arrows). C: DRG section from Pt(dach)Cl2-treated 
animals displaying eccentric nucleoli (solid arrows) and multinucleolated nuclei (hollow arrows). SEM backscatter 
generated image. x1500 magnification. 10 keV. Scale bar: 10 µm.  
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Control Oxaliplatin Pt(dach)Cl2
Cell diameterA (nm) 39.28 ± 1.656 27.24 ± 1.042 37.33 ± 5.517
Nuclear diameterA (nm) 13.9 ± 0.614 12.68 ± 1.296 13.56 ± 1.756
     % Cells with multiple nucleoli 10.8 11.4 22.72
     % Cells with eccentric nuclei^ 27.92 31.42 38.63
     % Cells with eccentric nucleoli^^ 53.15 74.28 63.63
Morphometric Analysis of Rat Dorsal Root Ganglia L4 Following Drug Treatment* 
Table 3.5.3.1
* Morphometric analysis of dorsal root ganglia cell bodies, nuclei and nucleoli was performed following drug treatment as described under 
Methods.   
A Means 
^ Percentage of these from small diameter DRG cell bodies (<20μm) as a function of all cells with eccentric nuclei as follows: Control: 22%, 
Oxaliplatin: 58%, Pt(dach)Cl2: 4% 
^^ Percentage of these from small diameter DRG cell bodies (<20μm) as a function of all cells with eccentric nucleoli as follows: Control: 38%, 
Oxaliplatin: 60%, Pt(dach)Cl2: 35%.
3.6 Summary of Findings  
Pt(dach)Cl2 produced no significant changes to rodent behaviour after four intraperitoneal 
injections; nor did it cause changes in spinal cord microglia and astrocyte morphology 
and activation or significant dorsal root ganglia axonal changes. Similarly, oxaliplatin 
produced no significant sensory alterations in the current investigation. However, there 
was a significant increase in astrocyte activation following oxaliplatin administrations in 
rodent spinal cord dorsal horns. Additionally, three rodents administered with oxaliplatin 
died prematurely; one following the first injection and two following the second injection. 
Oxaliplatin, therefore, had some effect on the health of the animals. A large portion of this 
investigation was the development and refinement of novel methodologies in the 
identification of platinum in dorsal root ganglia tissue. Platinum was detected in resin 
embedded DRG sections both in the tissue and the resin surrounding the DRG using full 
spectrum X-ray mapping. This proves that the concept can work in identifying platinum 
accumulation in tissues from chemotherapy drugs. However, future studies will require 
greater sensitivity and further refinement of the methodology. This study has advanced 
novel ways to visualise platinum in dorsal root ganglia whilst additionally developing ideas 
to improve detection in future studies.    
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CHAPTER 4 
DISCUSSION
Oxaliplatin in widespread clinical use is limited by the development of painful acute and 
chronic neuropathies (Ta et al. 2006). The mechanisms responsible for oxaliplatin-induced 
neuropathic symptoms are not fully understood; however, they are believed to result from 
the contributions of glia, atypical ion-channel activity and nervous tissue alterations (Ahn 
et al. 2014; Carozzi et al. 2015; Jung et al. 2017) that may manifest from platinum 
accumulation in nervous tissues (Ta et al 2006; Di Cesare Mannelli et al. 2013; Kanat et al. 
2017). This investigation sought to understand what effects repetitive oxaliplatin- and 
Pt(dach)Cl2-treatments had on dorsal root ganglion cell morphology and spinal cord glia. 
Additionally, this study aimed to develop novel techniques to investigate DRG platinum 
accumulation in order to understand whether clinically observable sensory allodynia and 
hypersensitivies result from platinum/tissue interactions.   

4.1 Behavioural Assessment
Oxaliplatin administration as part of human cancer treatments is limited by the 
development of acute and chronic sensory disturbances. Platinum-based 
chemotherapeutics have long been associated with pain, and despite its clinical 
relevance, the mechanisms driving oxaliplatin-induced neuropathic pain remain elusive. 
Acute oxaliplatin-induced neuropathies are unique among the platinum-based 
chemotherapeutics (Carozzi et al. 2015). Nocifensive responses manifest shortly after 
drug administration and typically resolve between cycles, however, there is a propensity 
for symptoms to recur with successive drug infusions (Renn et al. 2011; Carozzi et al. 
2015). The most common side-effects reported by patients involve the development of 
cold-evoked hypersensitivities (Liu et al. 2014) and mechanical pain (Park et al. 2009). 
Although acute symptoms can be debilitating and occur in upwards of 90% of patients 
(Argyriou 2015), the chronic phase is often more severe, requiring dose reduction or 
cessation (Kim et al. 2017). Painful, chronic proprioceptive neuropathic symptoms 
typically persist for years following drug withdrawal (Carozzi et al. 2015) and respond 
poorly to current therapeutic options (Descoeur et al. 2011; Argyriou 2015). Dose-
dependent platinum accumulation in dorsal root ganglia following cumulative drug 
administrations is thought to contribute to chronic oxaliplatin-induced neurotoxicity 
(Weickhardt et al. 2011). In the current study, intraperitoneal injections of either oxaliplatin 
(2.5 mg/kg) or its biotransformation product Pt(dach)Cl2 (2.39 mg/kg) were given to 
rodents every three days for a total of four injections in order to simulate the development 
of chronic oxaliplatin-induced neuropathic pain. However, when assessed for the 
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development of these symptoms, the rodents appeared unperturbed by the drugs. There 
were no observable significant differences in behaviour after four injections when 
compared with controls. In recent studies, however, oxaliplatin has been known to 
produce a quick-onset, transient cold hypersensitivity (Renn et al. 2011;  Ahn et al. 2014; 
Carozzi et al. 2015) which can manifest as a chronic cumulative cold-exacerbated 
sensory neuropathy following repeated infusions (Descoeur et al. 2011). Zhao et al. (2012) 
observed significant increases in escape behaviour scores in rodents 24-hours post-
injection and Di Ceasre Mannelli et al. (2017) recorded cold hypersensitivities 21 days 
after cumulative treatments. Cold hypersensitivities are thought to develop in rodents and 
humans through relationships with oxalate. In their study, Sakurai and collaborators (2009) 
reported cold hypersensitivity-like symptoms analogous to oxaliplatin treatments in 
rodents treated with oxalate. In the current investigation, however, oxaliplatin did not 
appear to produce cold-related pain-like behaviour assessed by the cold plate assay. This 
assay has the potential to invalidate results and produce incorrect interpretations. It relies 
heavily on the training and interpretation of responses by the observer who may 
unwittingly include or exclude pain-related behaviours. Other assessment criteria for cold-
associated nocifensive responses used in oxaliplatin research, such as the acetone spray 
test, are not without their own drawbacks and should be used and interpreted carefully. 

Mechanical allodynia occurs when a non-noxious mechanical stimulus, such as light 
pressure, is able to produce a nocifensive response. Mechanical sensitivity typically 
occurs several days after repeated drug cycles in rodent models of oxaliplatin-induced 
neuropathic pain (Kawashiri et al. 2011), although it may also occur in a similar time scale 
as cold hyperalgesia (Zhao et al. 2012) and after a single drug infusion (Jospeh & Levine 
2009; Hohmann et al. 2017). The aetiology of oxaliplatin-induced mechanical allodynia is 
not fully understood, however, unlike for cold hypersensitivity development, it is believed 
that oxalate is not involved in its development (Mihara et al. 2011). Instead, the 
diaminocyclohexane platinum (Pt(dach)Cl2) metabolite is a candidate, having been shown 
to produce mechanically stimulated nocifensive responses in rodents (Sakurai et al. 
2009). In this investigation, neither oxaliplatin nor Pt(dach)Cl2-treatments produced 
significant changes in mechanical sensitivity after four intraperitoneal injections when 
assessed by electronic von Frey. The length of the behavioural testing period may have 
influenced the assessment of drug-induced mechanically-evoked pain. In their 
Pt(dach)Cl2 study,  Sakurai et al. (2009) observed mechanical allodynia following 8 weeks 
of testing under blind conditions. The behavioural testing period in the current study 
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lasted only 12 days from the first injection. Additionally, Sakurai et al. (2009) used a 
dosing regimen almost double the current study for both drugs (4 mg/kg). This may affect 
the well-being of the animals and produce neuropathy-like responses. Indeed, in the 
current investigation three animals died prematurely, possibly from platinum toxicity 
following 2.5 mg/kg oxaliplatin treatments. Petkova and collaborators (2013) remark that 
genotoxic therapies have the ability to adversely affect patients, sometimes leading to 
death from the inhibition of normal cell growth and function. The current dosing regimen 
was chosen to be comparable with human dosing volumes in order to assess the 
capability of detecting platinum within tissues; while the dosing time frame was 
implemented to expedite chronic neuropathic symptom development. Several dosing 
regimens used in previous studies are outlined in Table 4.1. Each injection volume is 
different, so too are the dosing times and study durations. This high variability impacts on 
the consistent ability to reliably compare results across studies.  Therefore, to throughly 
assess the involvement of oxaliplatin and Pt(dach)Cl2 in the pathophysiology of 
chemotherapy-induced mechanical pain, assessment times and dosing regimes should 
be considered.
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Study Author Oxaliplatin dose Injection Timescale Blinded?
Descoeur et al. (2011) 1, 3 & 6 mg/kg Single intraperitoneal injection No
Di Ceasre Mannelli et al. 
(2013)
2.5 mg/kg 5 consecutive i.p. injections (3 weeks) Yes
Joseph & Levine (2009) 2 mg/kg Single intravenous injection No
Kawashiri et al. (2011) 4 mg/kg Twice weekly i.p. injections (4 weeks) Yes
Mihara et al. (2011) 4 mg/kg Twice weekly i.p. injections (4 weeks) Yes
Park et al. (2015) 3 mg/kg 5 consecutive i.p. injections (3 cycles) Yes
Sakurai et al. (2013) 4 mg/kg Twice weekly i.p. injections (4 weeks) Yes
Tsubaki et al. (2015) 6 mg/kg Two i.p injections over two weeks (day 0 & 7) No
Yoon et al. (2013) 2 mg/kg Four i.p. injections every two days Yes
Zhao et al. (2012) 1, 5 & 10 mg/kg Single intraperitoneal injection No
Table 4.1 Oxaliplatin dosing regimes used in various studies
i.p.: intraperitoneal 
The Hargreaves assay was first described in 1988 as a method to quantify heat 
thresholds in rodent hind paws upon application of an infrared heat source (Deuis et al. 
2017). At no time-point during behavioural training and after oxaliplatin- and Pt(dach)Cl2-
treatments were there any differences in paw withdrawal thresholds to thermal heat 
among the test groups. Similar findings are reported by Park et al. (2015) and Cheng et al. 
(2017), where oxaliplatin treatments failed to produce meaningful differences in paw 
withdrawal latencies to heat among treatment and control groups. Humans also do not 
report heat hypersensitivities. 

4.2 Immunohistochemistry 
Painful sensory information is transmitted by thinly myelinated Aδ and unmyelinated C-
fibres towards the dorsal horn of the spinal cord, where second order nociceptive neurons 
transmit painful information to the thalamus and cerebral cortex for processing (Gao & Ji 
2010; Liu & Yuan 2014). In addition to containing millions of neurons that convey signals 
towards and from the brain, the spinal cord contains 10 - 50 times more glial cells that 
support, protect and influence neurons (Gao & Ji 2010). Microglia are the resident 
macrophages of the central nervous system. Recent in vivo studies have shown that in 
healthy individuals, resting microglia patrol the CNS neuropil by continuously extending 
and retracting their process (Nimmerjahn et al. 2005; Wake & Fields 2011). Astrocytes are 
the most abundant glial cells in the CNS (Gao & Ji 2010) and are able to monitor and alter 
synaptic function through their close association with synapses (Chung et al. 2015). 
Increased glial expression and activation in spinal cord dorsal horns and supra-spinal 
sites may result in the decreased sensitivity thresholds reported by some researchers in 
oxaliplatin-treated rodents (Di Cesare Manelli et al. 2014). Microglia are widely distributed 
throughout the central nervous system where they respond to a wide range of physiology-
threatening stimuli (Tsuda et al. 2016). There is a growing body of evidence that suggests 
microglia are involved in chronic neuropathic pain development and maintenance through 
maladaptive nervous tissue functions (Inoue & Tsuda 2018). Studies that simulate 
peripheral nerve injury through nerve constriction and ligation have demonstrated robust 
microglia activation within the spinal cord (Jergova & Čížjová 2007; Dubovy et al. 2018). It 
is believed that microglia become activated following nerve injury through interactions 
with cytokines and chemokines that are released by damaged neurons (Liu & Yan 2014; 
Zhao et al. 2017). Activated microglia then undergo significant morphological and 
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biochemical changes that accompany proliferation within the spinal cord (Wen et al. 2011; 
Zhao et al. 2017). Spinal cord dorsal horn microglia in-turn respond to injury and 
contribute to chronic pain by secreting inflammatory mediators which can sensitise the 
sensory synapses of dorsal horn neurons (Malcangio 2016; Machelska & Celik 2016). Di 
Cesare Mannelli and collaborators (2013) reported an increase in spinal microglia density 
following repeated oxaliplatin administrations accompanying neuropathy development. 
Robinson and colleagues (2015), however, proposed that spinal astrocytes are involved in 
the development and maintenance of oxaliplatin-induced peripheral neuropathies without 
microglia involvement. This is supported by the current investigation which failed to 
observe an increase in the number of Iba1-expressing microglia in the dorsal horn of the 
spinal cord when examined by immunohistochemistry. Oxaliplatin treatments, however, 
appeared to significantly increase the number of GFAP-expressing astrocytes within the 
spinal cord of treated rodents. Similar to microglia, astrocytes proliferate and produce 
pro-inflammatory cytokines following peripheral nerve injury (Machelska & Celik 2016). 
Until recently, astrocytes were considered passive cells, maintaining homeostasis for 
synaptic neurons in the central nervous system and acting largely as supportive cells 
(Tembruni & Jacob 2001). All roles of astrocytes are not understood, however, there is 
increasing evidence supporting claims that astrocytes command more active roles within 
the nervous system. It is generally accepted that these cells have important functions in 
the development and physiology of the central nervous system (Barres 2008; Araque & 
Navarette 2010) and apart from maintaining normal cellular function within the CNS, 
astrocytes have been implicated in disease states (Barres 2008). Reactive astrocytes up-
regulate synapse-inducing genes which have the potential to cause neuropathic pain by 
inducing unwanted synapse formation (Barres 2008). In recent investigations, increased 
astrocyte expression has been observed in rat spinal cord sections and cortical regions 
following oxaliplatin administration, concomitant with sensory hypersensitivity and 
neuropathic pain development (Yoon et al. 2013; Di Cesare Mannelli et al. 2013).  

Similar astrocyte up-regulation was not observed in rodent spinal cord dorsal horns 
retrieved from Pt(dach)Cl2-treated animals. Pt(dach)Cl2, therefore, may not be directly 
involved in oxaliplatin-induced glial responses and the associated nervous system 
sensitization. Although it should be noted that Pt(dach)Cl2 is highly insoluble and there is a 
chance that the drug fails to make it to the tissues in appreciable quantities via 
intraperitoneal injections to affect glia. Nevertheless, oxalate from the biotransformation of 
oxaliplatin may play a role in nervous tissue dysfunction leading to astrocyte activation; 
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however, to our knowledge there have been no studies investigating this claim. This 
hypothesis is based on the fact that oxalate is known to induce mitochondrial dysfunction 
in kidney cells which contribute to the release of reactive oxygen species (Strzelecki et al. 
1989). Oxidative stress results in macromolecular and cellular damage (Ray et al. 2012) to 
which astrocytes may respond and become activated. Researchers studying oxaliplatin 
have shown that the drug is able to disrupt axonal mitochondria electron transport chains 
producing reactive oxygen species (Carozzi et al. 2015). More research is needed to 
determine if oxalate from oxaliplatin causes astrocyte activation. Recent studies have 
highlighted cold sensitivity development in rodents following oxalate infusions (Sakurai et 
al. 2009).  

4.3 Determination of Platinum Accumulation
An important feature of metal-based anticancer drug research involves exploring how 
these drugs distribute within tissues and cells. This is important because the 
dissemination of metal-based chemotherapeutics within tissues is linked with its efficacy, 
toxicity and any associated side-effects, as well as drug resistance (Lee et al. 2017). An 
abundant fenestrated capillary network coupled with an absent blood-brain barrier allows 
platinum drugs to accumulate in nervous tissues and gain access to sensory neurons 
(Kanat et al. 2017). The current investigation, therefore, sought to identify locations within 
DRGs that preferentially accumulate platinum from oxaliplatin and Pt(dach)Cl2 treatments 
using a novel methodology. 

4.3.1 Current Methods in Platinum Detection 
Chemotherapeutic platinum accumulation within blood plasma and tissues has largely 
been detected using destructive, but highly sensitive, techniques such as High Pressure 
Liquid Chromatography (HPLC) and Atomic Absorption Spectroscopy (AAS). Currently, 
platinum accumulation within dorsal root ganglia, and any inferences about its presence 
in the tissue leading to neuropathy development, have relied on Inductively Coupled 
Plasma-Mass Spectrometry (ICP-MS). This technique has the capability of detecting 
infinitesimal element concentrations within a sample. However, for analysis to proceed, 
the sample must first be destroyed, depriving researchers of any information regarding 
platinum distribution within the target tissue. In ICP-MS, samples are efficiently vaporised, 
dissociated, atomised, excited and ionised prior to analysation in which ions are 
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separated and quantified via mass spectrometry (Pröfrock & Prange 2012). Platinum was 
detected in dorsal root ganglia from oxaliplatin treated rodents using ICP-MS in studies 
conducted by Screnci et al. (1997), Screnci et al. (2000) and Kono et al. (2013). Screnci et 
al. (1997) observed that platinum from oxaliplatin preferentially accumulates in peripheral 
nervous tissues (DRG, sciatic and sural nerves) over the central nervous system. 

Inductively Coupled Plasma-Mass Spectrometry is an accurate, fast and sensitive 
technique, however, it offers limited information. The apparatus is able to determine the 
presence and concentration of an element of interest within samples; however, due to the 
sampling method, it cannot provide information to chemotherapy researchers on the 
location of platinum from chemotherapeutics within biological samples. This is important 
because the distribution of metal-based chemotherapeutics within tissues is linked with 
its efficacy, toxicity and any associated side-effects (Lee et al. 2017). This investigation 
sought to develop a methodology that preserves the sample and thereby addresses the 
technical limitations of the currently used instrumentation and methodologies in platinum 
tissue distribution analysis.

4.3.2 Full-spectrum X-ray Mapping  
Oxaliplatin is cytotoxic by forming intrastrand GG and AG DNA adducts within cancer cell 
nuclei (Chaney et al. 2005). Recent investigations examining the development of 
oxaliplatin-induced peripheral neuropathies have reported high levels of DNA adduct 
formation in oxaliplatin treated DRG cell nuclei in vitro (Ta et al. 2006). Investigating 
platinum accumulation within dorsal root ganglia cell bodies that contained a visible 
nucleus using full-spectrum X-ray mapping revealed platinum-containing sites within the 
cell body close to plasma membrane. The detected sites were small and easily 
overlooked using atomic number contrast in backscatter analysis at x2000 magnification. 
Instead scatter diagram zone-matched and quantification map pseudo-coloured images 
were created to highlight pixels that produced high platinum signals. Analysis revealed 
that platinum had accumulated near the periphery in DRG cell bodies. Further 
quantification of these sites for platinum was performed using energy dispersive 
spectroscopy, which validated the presence of platinum within the largest scatter diagram 
zoned cluster. Determination of platinum within the other sites could not be confirmed 
with EDS, and is most likely beyond the detection limit of the apparatus. Indeed, the 
signal obtained from the largest cluster is of limited EDS intensity. Additionally, platinum 
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was not found within dorsal root ganglia nuclei, presumably due to sensitivity limitations. 
It is believed that platinum-GG and platinum-AG intrastrand DNA adducts are formed 
following oxaliplatin administration in cellular nuclei (Saris et al. 1996; Chaney et al. 2005; 
Zayed et al. 2011) and arrest DNA transcription (Zhu et al. 2012). Platinum-DNA adducts, 
however, may adversely affect the functioning of dorsal root ganglia. Ta and collaborators 
(2006) observed inhibited DRG neurite outgrowth and increased dorsal root ganglion cell 
death (apoptosis) in vitro as a result of oxaliplatin administration accompanying adduct 
formation. DNA platinum adducts may be forming within tissues such as dorsal root 
ganglia which have the potential to result in neuropathy development; however, the 
current investigation failed to support this hypothesis due largely to instrument 
insensitivity. What’s more, the limited detection of platinum in DRG tissue may result from 
platinum diffusing out of the tissue during the resin embedding process, reducing the 
amount available in tissues for detection. In line with this hypothesis is a direct 
measurement of platinum within the resin surrounding DRG tissue. A full-spectrum X-ray 
map of a section of resin at the DRG/resin interface from an oxaliplatin-treated animal 
confirmed the presence of a large deposit of platinum outside the tissue. This area was 
further assessed by zone-matching scatter diagram data of high platinum signals onto a 
backscattered electron generated image. This confirmed that platinum formed a large 
deposit within the resin surrounding the DRG. Quantification maps validated the presence 
of platinum at this site, while energy dispersive spectroscopy of the resin-bound platinum 
region returned a signal several times larger than during tissue analysis; supporting the 
idea that platinum moved out of the tissue during resin processing. As platinum is not 
introduced at any other stage of the embedding processes except initially to the rats as 
an intraperitoneal injection, platinum that is detected within the resin most likely 
originated within the tissue. All other semi-thin dorsal root ganglion sections from either 
oxaliplatin or Pt(dach)Cl2-treatment groups that underwent full-spectrum X-ray mapping 
analysis did not reveal platinum in either the tissue or resin. Both drugs are highly 
insoluble in water (medium for injection). Therefore, it is probable that oxaliplatin and 
Pt(dach)Cl2 do not to make it to dorsal root ganglia in large enough quantities to be 
detected by X-ray mapping techniques when diffused throughout the DRG tissue 
following intraperitoneal injections. Similarly, platinum may wash out of the tissue during 
the perfusion and post-fixation processes. The post-fixation solution was not investigated 
for platinum in this investigation, however, it should be analysed for platinum in future 
studies using mass spectrometry.
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4.3.3 Secondary Ion Mass Spectrometry  
SIMS is a surface imaging technique in which the solid sample surface is analysed under 
high vacuum conditions through sputtering of the primary ion beam (Lee et al. 2017). It is 
increasingly being used in the investigation of metal-based chemotherapy drug 
distributions in tissues and cells due to its high spatial resolution (Gamble & Anderson 
2016). However, SIMS can also be a destructive technique depending on the type of 
SIMS used, and requires flat, vacuum-compatible samples (Vickerman & Gilmore 2009). 
Dorsal root ganglion sections were prepared in the same way as those for scanning 
electron microscopy analysis and X-ray mapping. For SIMS, however, silicon mounted 
semi-thin (1-5μm) resin-embedded DRG sections were analysed using a primary caesium 
beam. According to Pacholski & Winograd (1999), the use of caesium is beneficial in this 
work as it enhances the generation of negative ion formation, such as 195Pt-. Although 
increasing platinum-chemotherapy investigations are looking towards the use of SIMS, 
the current study failed to detect platinum in DRG tissue from oxaliplatin- and 
Pt(dach)Cl2-treated rodents. As the samples were prepared in the same way as those 
undergoing scanning electron microscopy analysis, platinum may have escaped the 
tissue into the post-fixation solution prior to resin embedding or during the resin 
embedding process itself and was thus unable to be detected using SIMS analysis. 
Although SIMS is more sensitive than X-ray mapping, the samples analysed using the 
technique may have been absent of platinum in quantities able to be detected by the 
apparatus, indeed platinum was found in only two samples under X-ray mapping 
conditions.  

The employment of NanoSIMS (not used in this study) has been successful in the 
characterisation of platinum accumulation in sub-cellular compartments in whole cancer 
cells. In their investigation, Legin et al. (2016) identified platinum accumulation in the 
nuclei and cytoplasmic compartments of Murine CT-26 cells. Similarly, Wedlock et al. 
(2013) observed significant platinum accumulation in cancer cell nucleoli of TriplatinNC 
treated cells. It is believed that a similar distribution of platinum occurs in non-tumour 
cells, particularly dorsal root ganglia nuclei and nucleoli where platinum may preferentially 
bind to DNA leading to neuropathy development (Sakurai et al. 2009). This is based on 
research conducted by Sprowl et al. (2013) that investigated oxaliplatin’s ability to cross 
DRG cell membranes by way of OCT2 channels and ICP-MS studies confirming 
oxaliplatin accumulation in dorsal root ganglia from treated rodents concurrent with 
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neuropathic symptom development. However, our current understanding is that the sub-
cellular distribution of platinum in sensory ganglia has not been investigated. Knowledge 
regarding the distribution of metallodrugs such as oxaliplatin in nervous tissues following 
chemotherapy treatments is important to our understanding of their effectiveness and 
roles in side-effect development (Lee et al. 2017). 

4.3.4 Mass Spectrometry  
Mass spectrometry analysis of oxaliplatin confirmed that the drug undergoes rapid non-
enzymatic conversion into Pt(dach)Cl2 when in the presence of saline (chlorine). This 
supports the work conducted by Ip and colleagues (2008) who identified that oxaliplatin in 
a solution of saline converted to Pt(dach)Cl2  when analysed using high pressure liquid 
chromatography. Investigations into the time scale of this conversion have revealed that 
half of the oxaliplatin (t1/2) in a mixture of rodent blood in vitro underwent alteration into 
Pt(dach) complexes such as Pt(dach)Cl2 within one hour (Luo et al. 1999b). Luo et al. 
(1997) reported this conversion of t1/2 oxaliplatin at 41 minutes in whole blood. Similarly, 
Allen et al. (1999) documented rapid oxaliplatin conversion into several biotransformation 
products within hours of administration into whole blood, with oxaliplatin undetectable 
two hours post injection in the plasma ultra-filtrate and urine of human patients. The rapid 
conversion of oxaliplatin into other complexes enables it to form DNA adducts in 
cancerous cells (Raymond et al. 1998). Upon entry into the cell, a chloride ion dissociates 
form the Pt(dach) complex enabling binding to guanines to form DNA mono-adducts 
(Raymond et al. 1998). In patients, oxaliplatin binds predominantly with erythrocytes 
(Gamelin et al. 1997; Graham et al. 2000), however, this does not act as a store of the 
drugs, being non-interchangeable with blood plasma (Pendyala & Creaven 1993). 
Pendyala & Creaven (1993) reported 37% of the total platinum from administered 
oxaliplatin was bound to red blood cells at t1/2. The determination of platinum 
concentration in blood following administration was performed using high-pressure liquid 
chromatography (Luo et al. 1997; Luo et al. 1999b) and inductively coupled plasma-mass 
spectrometry (Gamelin et al. 1997). Although these techniques are sensitive, they possess 
limitations; most notably samples are destroyed prior to analysis, therefore, information 
regarding element bonding can not be elucidated. In the current investigation, 
electrospray ionisation mass spectrometry without liquid chromatography was utilised to 
determine platinum accumulation within oxaliplatin and Pt(dach)Cl2-treated tissue. 
Platinum was not detected within either spinal cord or dorsal root ganglia as it may be 
below the detection limit of the Waters Xevo Quadrupole-Time of Flight mass 
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spectrometer. Researchers have proposed that platinum from platinum-based 
chemotherapeutics contributes to neuropathic pain by preferentially accumulating within 
DRG tissue due to the lack of a blood-brain barrier (Screnci et al. 1997; Holmes et al. 
1998; Kono et al. 2015; Kanat et al. 2017). Kono and colleagues (2015), utilising 
inductively coupled plasma-mass spectrometry (ICP-MS), discovered that DRG platinum 
accumulation is directly correlated with oxaliplatin-treatment duration, and after 8 weeks, 
platinum accumulation in L4-6 DRG was approximately 15 ng/rat. Similarly, Holmes et al. 
(1998) reported a dorsal root ganglia platinum concentration of 0.945 μg following 4mg/kg 
oxaliplatin injection twice weekly for 4 weeks using ICP-MS. Electrospray ionisation mass 
spectrometry without liquid chromatography may have limited the current investigations 
ability to elucidate platinum concentrations in treated tissues. However, it was required to 
understand the transformation of oxaliplatin within tissues and solutions, and was used to 
confirm previous reports that oxaliplatin undergoes rapid conversion into Pt(dach)Cl2. In 
the current investigation, neither blood nor urine was collected for analysis, however, it 
has been previously reported that platinum binds irreversibly with erythrocytes and is 
eliminated from humans through urinary excretions (Graham et al. 2000) and thus should 
be further investigated. 

4.4 Review of the Methodology 
Behavioural measures of oxaliplatin-treated rodents by various researchers indicate a 
rapid onset of cold-related hypersensitivities followed by delayed mechanical allodynia 
(Saif & Reardon 2005; Di Cesare Mannelli et al. 2013; Tsubaki et al. 2015; Park et al. 
2015). Measurement of these parameters in the current investigation was done following 
double-blinding. In the cited literature, several researchers do not make explicit mention 
of the blinding of their investigators which may influence the interpretation of the results 
(Descoeur et al. 2011; Zhao et al. 2012; Tsubaki et al. 2015). Adoption of certain 
assessment apparatuses can additionally confound results. Yamamoto et al. (2016) and 
Jung et al. (2017) assessed mechanical allodynia following oxaliplatin injections using 
manual (classical) von Frey techniques and the up-down method. Based on a logarithmic 
scale, deviation of withdrawal thresholds is assessed by a series of von Frey hairs. A 
reduction in the hair needed to evoke a response is recorded as a ten-fold increase in 
sensitivity and may, therefore, be largely inaccurate. To account for this inherent 
discrepancy with classical von Frey measurements, the current investigation used an 
electronic assay. This technique measures the precise pressure required for a withdrawal 
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response compared to the 50% withdrawal responses in the classical assay (Martinov et 
al. 2013). 

What should also be considered, and was not originally explored, is the medium in which 
oxaliplatin and Pt(dach)Cl2 are dissolved. In the current investigation, both drugs were 
vortex mixed in 0.9% saline solution moments prior to injection. While many oxaliplatin 
studies utilise intraperitoneal injections as the primary mode of drug delivery, most of 
these dissolve oxaliplatin in 5% glucose made up with distilled water. These studies then 
report the development of cold and mechanical neuropathies. Table 4.4.1 summaries 
these studies. The lack of behavioural symptoms following drug administration in the 
current study may, therefore, result from the drugs not moving into the rodent circulation 
and then into tissues in appreciable amounts due to improper suspension in the vehicle. 
Future studies should incorporate 5% glucose as the drug vehicle.

A number of methodologies throughout the investigation were used in original ways to 
determine locations within rat dorsal root ganglia that preferentially accumulate platinum. 
While scanning electron microscopy detected tissue-bound platinum, this was at the 
detection limit of the Jeol 7001 SEM. Although not definitively detected in the current 
investigation, platinum is most likely accumulating in dorsal root ganglia, having been 
detected in tissue via inductively coupled plasma-mass spectrometry by a number of 
researchers (Sprowl et al. 2013; Kono et al. 2015). The current findings are most probably 
explained by platinum from both oxaliplatin and Pt(dach)Cl2 diffusing out of tissue during 
processing. Examination of the resin surrounding the DRG confirmed this in one sample. 
During the resin embedding process, DRGs are post-fixed in paraformaldehyde and 
several washes in ethanol, acetone and resin before polymerisation. Oxaliplatin and 
Pt(dach)Cl2 being highly insoluble in water, may preferentially move out of the tissue into a 
more soluble medium, such as the resin. Biological tissue is difficult to image and analyse 
in the vacuum of the SEM without prior processing (Fischer 2012). Water within the tissue 
boils in the vacuum destroying the sample. There are other techniques that may be 
employed without embedding the tissue in resin such as critical point drying prior to SEM 
analysis, however, this may prove impractical for this investigation as it still requires 
processing in ethanol and once dry, cannot reliably be sectioned. To circumvent the 
problem, the resin that the tissue is incubated in prior to polymerisation may be examined 
either by full spectrum X-ray mapping or through mass spectrometry. The epoxy resin is 
made fresh on the day of embedding and never contacts platinum. Detection of platinum, 
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therefore, in this resin would act as an indirect measure of platinum with tissues of 
interest, having come only from the sample itself. However, this technique cannot answer 
questions relating to tissue accumulation sites of platinum.

The current literature that investigates platinum as a culpable mechanism of 
chemotherapy-induced peripheral neuropathies are limited in showing that platinum was 
detected in tissues but not where it preferentially accumulates. The current study 
developed a novel approach to assist in answering this later question, with platinum able 
to be detected within DRG tissue and the resin surrounding the sample through full-
spectrum X-ray mapping. This new investigative technique also had several limitations. 
Although platinum was discovered in dorsal root ganglia sections obtained from 
oxaliplatin-treated animals in conjunction with an astrocytitic response in the spinal cord, 
similar results were not found for Pt(dach)Cl2. There is a possibility that the drug, following 
intraperitoneal injections does not make it to the target tissues investigated in this study. 
The metabolite, like oxaliplatin, is highly insoluble. Previous studies (Sakurai et al. 2009) 
that identified that Pt(dach)Cl2 affected rodents focused on behavioural studies and did 
not investigate the accumulation of the drug within tissues. Further work needs to 
incorporate an independent verification that the drugs are making their way into the target 
tissue. Refinement and improved resolution of this methodology will assist further 
investigations.
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4.5 Morphometry Assessment 
Oxaliplatin produces noticeable acute and chronic neuropathic symptoms following 
infusion. These sensory disturbances may result from nervous tissue dysfunction and 
structure alterations. Although the current investigation did not examine sensory nerve 
excitability changes following oxaliplatin and Pt(dach)Cl2 administrations, recent insights 
involving humans have disclosed axonal excitability changes following a cumulative 
clinical dose of oxaliplatin (776 mg/m2) in sensory nerves concomitant with axonal 
sensory neuropathy development (Park et al. 2009). Meanwhile, rodent studies describe 
the development of sensory disturbances accompanying decreased peak latencies and 
amplitudes with reduced sensory nerve conduction velocities following oxaliplatin 
treatments (Renn et al. 2011; Lee et al. 2012). Axonal excitability variations are believed to 
result from the altered function and dysfunction of axonal ion channels (Starobova & 
Vetter 2017). Additionally, functional deficits may arise from structural axonal changes 
including fibre loss, axonal degeneration and demyelination as a result of platinum 
metalloid drug/nervous tissue interactions (Starobova & Vetter 2017).

Dorsal root ganglia contain the cell bodies of sensory afferent nerves and are particularly 
vulnerable to chemotherapeutic drug accumulation (Krames 2014). Zheng and 
collaborators (2011) reported mitochondrial electron transport chain disruption in DRG 
neurons following oxaliplatin treatments which they claim have deleterious effects on 
axonal mitochondria. Furthermore, prolonged exposure to oxaliplatin has been reported 
to contribute to increased apoptosis-mediated cell death among DRG sensory neurons 
(Scuteri et al. 2010). Damage and disruption of large myelinated fibres has been observed 
in peripheral nerves from cisplatin-treated individuals, while unmyelinated axons remain 
untouched (Thompson et al. 1984). Kono and colleagues (2015) reported axonal 
degeneration of rat DRG fibres following oxaliplatin treatment. High magnification 
scanning electron microscopy found damage to the myelin of large fibre axons in control, 
oxaliplatin and Pt(dach)Cl2-treated dorsal root ganglia, however, small fibre diameter 
axons appeared undamaged amongst all treatment groups. Damage preferentially 
affected the large fibres in the ventral root and DRG, while unmyelinated C-fibre area was 
unaffected. Oxaliplatin and Pt(dach)Cl2 did not significantly alter dorsal root ganglia and 
ventral root axonal G-ratios for both damaged and non-damaged fibre populations when 
compared to controls. Although damaged axons consistently reported smaller G-ratios 
than undamaged fibres, control animals, as well as the drug-treatment groups, reported 
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the same difference; therefore, it is unlikely this change was drug induced. In contrast to 
these findinds, Tsutsumi et al. (2014) reported larger G-ratios in rodent sciatic nerve fibres 
following cumulative oxaliplatin injections related to axon demyelination. 

Atrophy of sensory nerve cell bodies has been described following oxaliplatin 
administration as a morphological basis for aberrant sensory nerve activity (Jamieson et 
al. 2005) and neuropathy development (Weickhadt et al. 2011). In the current study, DRG 
cell body and nuclear diameters were significantly reduced in oxaliplatin, and to a lesser 
extent, Pt(dach)Cl2-treated rodents. Renn et al. (2011) recorded a similar reduction in DRG 
cell body diameter accompanying oxaliplatin administration and chronic neuropathy 
development. Reduced cell body diameter is suggestive of neuronal atrophy (Renn et al. 
2011). Accompanying this assessment was the examination of the number of cells with 
multinucleolated nuclei. Rodents treated with either oxaliplatin or Pt(dach)Cl2 contained 
significantly higher proportions of cells with multinucleolated nuclei compared to control 
animals. Di Cesare Mannelli and collaborators (2013) reported oxaliplatin-evoked changes 
in sensory behaviour in line with a higher ratio of DRG neurons with multiple nucleoli while 
Cho et al. (2016) described greater sensory neuropathy development in those animals 
with the highest percentage of neurons with multiple nucleoli within spinal ganglia. More 
work is needed to confirm if there is a direct correlation between multiple nucleoli and 
oxaliplatin-related neuropathies. Transcription of ribosomal RNA occurs within the 
nucleolus (Tomiwa et al. 1986), changes in its structure may therefore result in a reduced 
ability for the neuron to counter platinum-induced cellular disruptions. Concluding the 
morphological examination of dorsal root ganglion neurons revealed that DRGs from 
oxaliplatin and Pt(dach)Cl2-treated rats possessed more eccentric nuclei and nucleoli than 
controls. The effects of chemotherapeutics are often evaluated by assessing the neuronal 
morphology of random dorsal root ganglia sections (Höke & Ray 2013). Studies evaluating 
oxaliplatin have implicated multinucleolated and eccentric nuclei and nucleoli as signs of 
neurotoxicity (Holmes et al. 1998). 

4.6 Conclusion 
Oxaliplatin produces acute sensory neuropathies which can development into chronic 
neuropathic pain following repeated administrations in humans. The culpable 
mechanisms in the development of chemotherapy-induced pain, however, remain elusive. 
In the current investigation, four intraperitoneal injections of oxaliplatin and Pt(dach)Cl2 
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did not produce significant changes in behaviour or dorsal root ganglia cell morphology. 
However, astrocyte activation in spinal cord dorsal horns following oxaliplatin 
administrations were observed and may contribute to the development of pain states 
reported by other researchers. Platinum accumulation in dorsal root ganglia has been 
associated with causing maladaptive neuron function leading to sensory 
hypersensitivities. Knowledge regarding the dissemination of metal-based drugs within 
tissues is important for understanding their efficacy and toxicity. The development of a 
novel technique for the identification of platinum within DRG tissue and resin was 
successful using full spectrum X-ray mapping. The culpable mechanisms in the 
development of oxaliplatin-induced peripheral neuropathies are likely multifactorial and, 
therefore, require continued research. 
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